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ABSTRACT 
Four human osteosarcoma cell lines (MNNG, TE85, MG63, and G292) and a 
human-derived osteosarcoma metastatic to rnurine long (MLM) were transduced in virro 
using retroviral vectors containing the Herpes simplex thymidine kinase (HS-tk), human 
interleukin 2 (IL2). and BgaIactosidase (BAG) genes. Each osteosarcoma cell line was 
stably transduced, and the HS-tk gene effectively conferred ganciclovir (GCV) 
susceptibility to transduced cells. Each cell line showed a bystander effect (whereby wild 
type tumor cells are killed by co-incubation with HS-tk positive tumor cells and GCV). 
NlNlVG cells were used to develop a series of experiments in athymic nude mice 
to investigate the utility of gene therapy for the treatment of experimental osteosarcomas. 
Subcutaneous implants of mixtures of tumor cells and HS-tk vecbr producer cells (vpc) 
resulkd in the development of tumors which were completely cured upon administration 
of GCV. Subcutaneous implant sf mixtures of transduced and wild-typc cells resulled in 
a potent bystander effect upon administration of GCV, with complete tumor ablation 
when as little as ten percent of the cells were HS-tk positive. A significant anti-tumor 
response was seen against primary tumors comprised of unmodified cells when a 
secondary tumor of transduced cells was induced at a distance of one centimeter, which 
supports a soluble bystander factor model. The presence of 1L2-transduced cells 
significantly improved the efficacy of treatment, suggesting a synergy between the HS-tk 
and IL2 gene products. A significant anti-tumor response was seen in the treatment of 
established osteosarcomas by the injection of HS-tk vpc. 
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lNTRODUCTION and REVIEW OF THE LITERATURE 
Osteosarcoma 
Definition and 1n~idence.l.~ Osteosarcoma is a primary malignant tumor of 
bone, deriving from primitive bne-forming mesenchyme and characterized by the 
production of osteoid tissue or immature bone by the malignant proliferating spindle cell 
s t r ~ m a . ~  Osteo~arcoma is the most common bone cancer of childhood and adolescence, 
accounting for 60% of the 5.6 cases per million children, and 20% of all bone tumors, 
This disease afflicts males more frequently than females, at an 8:5 ratio, but shows tittle 
preference for race or geographic tocation. In the United States, there are about 900 new 
cases per year.4 
Osteosarcoma strikes at a peak age range of ten to 25 years, but it has been 
reported in toddlers (the youngest k i n g  35 months) and the elderly. The peak incidence 
for females is 13.5 years, and for males is 14.5 years.2 Because these ages correspond 
with the typical onset of the adolescent growth spurt, a relationship between rapid bone 
growth and development of cancer is s~~ges t ed .5  Indeed, the greater incidence among 
males may be related to the larger volume of bone formed during the growth period. 
Patients with osteosarcoma tend to be tall for their age, typically in the 80th percentile or 
greater for heightA2 
Histological S~btypes .~*~*8 Conventional subciassifications of osteosarcomas 
include Four major forms, and at least four rare variants, a11 of which are microscopically 
distinct. The osteoblastic subtype, involving malignant bone as the primary neoplasm, is 
the most common type, accounting for 44% of all osteosarcoma cases. The 
chondrob~astic subtype, first involving malignant cartilage, ranks second with 27% of all 
cases. An anaplastic subtype is seen in 17% of cases. A fibroblastic subtype, involving 
malignant stroma, has been identified in nine percent of all cases. About three percent of 
patients show a histological mix of these types. 
Rare variants include parosted Cjuxtacortical) and periosteal forms, which are 
seen in five percent of cases. Both are superficial, arising from the cortex and not 
involving the bone marrow. These types are more frequently seen in patients over 30 
years of age and are reported to be stubborn to treatment but seldom metastatic. Another 
infrequently observed (three percent) subtype is telangiectatic, which is characterized by 
giant cells and a cystic tumor. The most rare form (one percent) of the disease (and the 
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most deadly) is multifocal sclerosing osteosarcoma. This type is only seen in children 
under tcn years, and is invariably fatal. It involves multiple primary tumors in the ends of 
most long bones, and it tends to disseminate ragidly to the tungs and soft tissues. 
Clinical Course 2-9. The onset of osteosarcoma typicaliy involves pain due to 
tension placed on the pcriosteum. The pain is slight and sporadic, and has been compared 
lo a sprain, rheumatism, or arthritis. This vague complaint generally precedes tumor 
appearance by days to months. The sitc of the primary nmplasm is variable and has 
prognostic value. Half of all osteosarcoma cases are seen in the femur; 80% of these are 
in the distal portion of the bone. Thc disease is also seen in the nud- and proximal femur, 
the proximal tibia, and the proximal humerus. Osteosarcoma arises infrequently (15-20% 
of all cases, but less than ten percent of pediatric cases) in axial bones such as the pelvic 
bones, vertebrae and ribs. Primary cancer in the jaw is reported to occur in seven percent 
of cases, and typically displays an aggressive dinical course. Rarely, osteosarcoma arises 
in the fibula, ulna. radius, metacarpals, and melatarsals. Osteosarcomas of the long bones 
tend to originate a1 the metaphysis. Osteosarcomas generally grow very rapidly, with a 
median doubling time for tumor volume of 34 days. 
." Much of the mortality associated with osleosarcama is due 
to metastasis of malignant cells through the blood to distant, often multiple sites. Over 
80% of metastasis is to the lungs, and 1530% is to olher bones. Less common sites are 
the pericardium, kidneys, adrenal glands, and brain. Ten to 20% of patients present with 
visible rnaerometastases, and a greater proportion (perhaps- 40%) have microscopic 
metastases. A significant percentage of patients experience metastasis at some p i n t  
during the course of the disease. The two-year survival rate of metastatic osteosarcoma is 
30% or Iess. 
Diagnosis.2 The external appearance of the area overlying the tumor may vary 
widely among patients, depending upon the site, progression, and other factors. 
Typically. the overlying slun will not ulcerate but may be stretched taut and have an 
increased temperature; the tumor may be palpable, and richly vascular tumors may 
pulsate. Twenty percent of patients with osteosarcoma will experience a pathological 
fracture in the affected bone; this is their initial reason for seeing a physician. The 
classical demonstration of an osteosarcoma is done radiologically; X-ray analysls will 
show a "sunburst" appearance of radiating ostcoid cell prodrlction from the primary lesion 
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to the surrounding soft tissue. Half of patients present with an elevated serum alkaline 
phosphalase level, which may be of diagnostic significance. 
Staging Information2. Clinical cases of osteosarcoma are divided into three 
categories. In stage I, or low grade, osteosarcoma the tumw is lwalized to the bone of 
origin; this may represent an early tumor or a Iess aggressive subtype. Tumors at this 
stage (and stage 11 below) are subdivided into intramedullary and extramedullary 
categories, depending upon the site uf development. With the best available therapy, the 
two-year survival at this stage is  70-90%. 
Stage 11, or high grade, osteosarcomas involve wcll-developed or more aggressive 
tumors. Tumors in this stage remain localized to the bone of origin, but "shp metastases" 
(smaller, secondary tumor foci) may be present, indicating a worse prognosis.12. The 
two-year survival at this stage is @-a%. 
Stage 111, or metastatic osteosarcoma, involves the spread of the cancer through 
the hematogenow route to distant sites in the body. Ninety percent of metastatic disease 
is to the lung. These patients have high risk of pulmonary hemorrhage and Lailure, 
obstruction of the pulmonary vessels, and other life-threatening conditions. The second 
most common site of metastasis is to another bone. With the best available therapy, the 
two-year survival rate at this stage is 30% or less, and the five-year survival rate is 
generally below 20%. Patients who survive beyond five years often experience no further 
trouble, in whch case they are considered to be cured of the disease.13 
Prognostic featuresll3.13. Many parameters have a significant inf uence on the 
clinical course of osteosarcoma. The site of the primary tumor has perhaps the greatest 
predictive importance. Tumors of the limbs have a better prognosis than do tumors of the 
axial skeleton. Tumors of the metacarpals, metatarsals, and tibia tend to be the most 
favorable, while tumors of the claviclc, scapula, other nonexpandible bones, and upper 
half of the femur often have less favorable outcomes. Osteosarcomas of the skull, 
vertebrae. and pelvis have a very poor prognosis due to the limitations in treatment 
avenues. Moreover, a distai location of a tumor is more favorable than is a proximal 
location. Smaller tumors generally have a better prognosis. 
The age of the patient is also an important factor; patients between the ages of 20 
and 50 typically fare better. Younger patients often develop tumors which are 
biologically more belligerent, and older patients generakly do not respond as well to 
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treatment. Female patients typicdy fare better than do  male patients, The duration of 
symptoms prior to treatment has a predictive value; surprisingly, a longer duration of 
symptom carries a better prognosis, as high grade tumors are usually less tolerable. 
Tumor cell histology is mother indicative factor. Periosteal and perosteal types 
have favorable prognoses. Differences among the other types may be only intidental. It 
has also been r e p o d  that increased tumor cell ploidy may be negatively correlated with 
the prognosis.8 
The serum levels of at least two enzymes have a significant predictive vakueG. 
Patients presenting with elevated LDH (lactic dehydrogenase) levels have a long term 
survival rate which is reduced by 50% compared to patients with low LDH levels. 
Elevated alkaline phosphatase levels indicate a greater risk of metastasis. The presence 
of the HLA-A3 haplotype has been associated with a poor prognosis. l4 The prognmis for 
metastatic &sease depends upon a number of variables, including surgical resectability, 
number of' Iung nodules (three or fewer are favorable), and recurrence frquency.l5?14 
E t i ~ l o g y . ~  The cause of osteosarcoma remains unknown, but multiple factors 
may be involved. Neoplasms in long bones tend to arise near the growth plate, where the 
greatest increase in length and size occurs. Thus, random aberrations of the normal 
process of bone growth and remodeling may contribute to the onset of osteosarcum. 
The correspondence of cases with the adolescent growth spurt suggests that changing 
hormone levels may have an influence. 17 
Mounting evidence strongly irnplicales a genetic basis for the disease. 18 Before 
molecular analysis was availabke, multiple cases of osteosarcorna within families were 
diagnosed at a higher level than dictated by chance, and sixteen sets of siblings with the 
disease have been reported.19 More recently, allele losses at specific loci of transformed 
cells have been identified,20 and many of these loci correspond to the sites of tumor 
suppressor genes. Specificdly, a deletion along the short m n  of chromosome 3 is seen in 
75% of osteosarcorna patients. A deletion along the short arm of chromosome 13 
(corresponding to  the RBI tumor suppresser gene) is seen in 688 of patients. In the 
osteosarcomas of 72% of patients, a loss along the long arm of chromosome 17 
(corresponding to the pS3 tumor suppresser gene21) is observed; loss at this loci is 
prognostic of early lung metastmis.22 Finally, 64% of jmtients show a deletion along the 
short arm of chromosome 18. These statistics suggest that many patients undergo 
multiple deletions, which may indicate that the propensity for the development of the 
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disease is dependent upon sequential, recessive mutations. as was first generally 
hypothesized fbr cancer over two decades ago .23 
Cytogenetie abnormalities are often seen in osteomrconma cells, These cells tend 
to be highly aneuploid, with up to eight times the normal diploid chromosome number. A 
direct relationship has been demonstrated between the percentage of diploid tumor cells 
and the survival of the patient." 
Ionizing radiation 1s implicated in three percent of osteosarcorna cases; in these 
cases, cancers developed after an average interval of 12-16 years. Moreover. four percent 
of all patients wlth osteosarcorna have had radiotherapy for other turnors.3 
Oncogenesis may also be related to growth factor abnormalities. Some 
osteosascoma cells have been found to overproduce the cytokine PDGF (platelet-derived 
growth f a c t ~ r ) ; ~  this is thought to result from high expression of the c-sis proto- 
onc0gene.W Significant amplification of the c-nayc proto-oneogene has also been evident 
in osteosarcorna tumor tissue. Osteosarcoma cells also tend to have an inappropriately 
high number of growth factor receptors,g which may contribute to the transformation 
process. 
There arc also several genetic diseases which tend to predispose patients to the 
development of osteosarcoma. For example, among patients with retinoblastoma, half of 
all secondary malignancies are osteosarcoma, and this type of cancer arises 2000 limes 
more frequently in the skull and 500 times more frequently in the extremities than the rate 
for the general pclyrulation.8 Among patients with Paget's disease (a noncancerous disease 
involving bone deformity and increased osteoblastic activity), two percent develop 
osteosarcorna; multiple bone involvement is frequent, and these patients generally have a 
poor prognosis.25 Finally, there is a significantly higher rate of asteosarcoma among 
patients with the congenital disease osteogenesis imperfecla.2 
Conventional treatment. Osteosarcomas are generally difficult to manage. 
Standard treatment for osteosarcoma has traditionally involved amputation of the affected 
limb at the joint proximal to the affected bone. Until 1972, amputation was the only 
available treatment course, which had limited success and invariably changed the quality 
of these patients' lives.26 In  a thirty-year study (concluded in  1976), 1256 patients were 
treated with surgical ablation; 50% developed metastasis within six months, and 248 
(19.78) survived five years after diagn0sis.2~ More recently, limb salvage prosedupes 
(including autotogous grafts, allografts, and endoprothesis) have been intraduced.B The 
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goals of this surgery are the complete removal of the tumor and avoidance of local 
recurrence while reconstructing a functional extremity. However, these types of 
procedures often carry an increased risk of recurrence without offering a significant 
benefit in terms of physical and psychological r e ~ o v e r y . 2 ~ ~ ~ ~  For osteosarcomas not 
involving the extremities, reductive surgery is indicated, and the prognosis is generally 
poor. 
Osteosarcomas are generally radiation insensitive and relatively drug-resistant. 
However, studies in 1981 and 1982 showed a significant benefit of post-operative 
chemotherapy, which was aimed at eliminating micrornetastx~ses.~~*32 More recently, 
pre-operative chemotherapy has been used to shrink the tumor mass prior to surgery; this 
also seems to be a good prognosticator of overall success, as responders tend to have 
fewer recurrences. Also, the response to pre-operative chemotherapy allows a 
determination of the drug sensitivity of individual cancers, and allows the post-operative 
therapy to be designed accordingly.33 Aggressive chemotherapeutic regimens show the 
greatest efficacy (as well as the greatest toxicity), and involve a multi-drug combination 
of any of the following: adriamycin, cisplatin, high-dose methotrexatc, and 
ifosfamide.34.35 
The treatment of metastases to the lung is generally disappointing, and usually 
involves thoracotorny to remove the portion of the lung which has undergone malignant 
transformation. Late-appearing (i.e., six months post-operative or later), single 
metastases have a better prognosis than do earlier or multiple metastases. However, the 
overall two-year survival of these patients is generally below 30%.36 Patients with 
metastases to bony sites tend to do less we11.37 
The outlook for osteosarcoma patients is improving. However, the most recent 
available data shows that, with surgery and chemotherapy, 40% of ali osteosarcoma 
patients experience relapse within five years. Secondary episodes seem to be more 
debilitating and less amenable to treatment, as only 30% of relapsing patients survive 
beyond five years.3 
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Gene Therapy 
Gene therapy may be defined as a technique in which a functioning gene is 
inserted into the somatic cells of a patient to correct an inborn genetic error or to provide a 
new functioa to the cell. The use of genetic therapy lo treat h u m  disease first becamc 
conceptually feasible with khe development of recombinant DNA technology, and has 
since progressed rapidly from speculation to reality.38 
General Principles of Gene Delivery. Two basic approaches are possible with 
regard to gene delivery to tumor cells. Flrst, cells can be taken out of the body, 
genetically-altered ex vivo, and then reimplant&. Classical means of gene transfer include 
a variety of techniques. Models for chemical transfer have included transfection by 
coprccipilation with calcium phosphaic or dcxtran, and the use of plycations or plylipids 
to complex with the DNA of interest . In t h s  system, the mixtures are introduced to a 
suspension of recipient cells; the chemicals disturb the plasma membrane to admit the 
D N A . ~ ~  Physical techniques have included eleclroporation and microinjection. Each of 
these methods are nontargeted and relatively inefficient, as integratioii may occur in less 
than one percent of the cells.4 More recently, ex vivo alteration has been donc using 
retroviral vectors. 
The second basic approach in clinical gene transfer is in vivo gene transfer. l n  vivo 
gene therapy has the advantage of circumventing tumor cell culture. In culture, cells from 
many tumors do not grow for a sufficient duration to permit genetic modification. In 
addition, this procedure is costly and labor intensive. One variation of this approach is to 
gmSt rnurine retroviral vector producer cells (VPC) into tumors. WghIy effective gene 
transfer can be accomplishd, as the VPC continuously produce vectors within the tumor. 
En xenogeneic models, murine VPC survive approx~mately two weeks and ate thought to 
be able to actively produce retroviral vectors over that time period. Since only a portion 
of the tumor cells is undergoing mitosis at a given point in time, the constant exposure of 
cells to the retroviral vectors increases the likelihood of genetic integration. Accordingly, 
the efficiency of transduction is greater than that which can be accomplished with 
injections of retroviral supernatants. 
The Clinical Inception of Gene Therapy. An ex vivo method of gene therapy 
employing retroviral delivery was utilized in the first trial of human gene therapy for 
adenosine deaminase (ADA) deficiency, a form of severe combined immunodeficiency, 
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which began in In this protcxol, T-lymphocytes were removed from two children 
with the disease, transduced ex vivo with retroviral vectors containing a normal copy 01 
the adenosine dearninme gene, and then re-infused. Twenty-ehree intravenous infusions of 
geneticafly altered autologous T-celis have been administered to date to each child. Both 
children show evideace of improved immune function and neither has demonstrated any 
evidence of adverse effect due to the genetically-altered cells.42-43 
The first gene marking experiment in humans also utiliz,ed ex vivo delivery by 
retroviral vectors. This study involved the treatment of 10 patients with autologous tumor 
infiltrating lymphocytes (TIL) that were transduced ex vivo with a retroviral vector 
encoding the neomycin resistance (NeoR) gene. None of these patients have demonstrated 
any untoward effects secondary to receiving the geneticall y-altered cells.# 
The first cancer gene therapy protocol in 1991 was a direct extension of the 
NeoFUTIL gene marker protocol. Here, the gene for tumor-necrosis factor (TNF) was 
incorporated into the retroviral vector.45 This gene is a powerful anticancer agent in 
experimental animals, but the induction of serious toxicity in patients receiving low levels 
of TlVF underlined the need to study clinically relevant levels for this cytokine.& Since 
this time, the use of other immonostirnlalatory genes (such as IL2) in gene therapy 
protocols has k e n  under intense investigation. 47 
Retraviral V e ~ t o r s . ~ . ~ ~  A retrovird vector is a genetically modified retrovirus in 
which a portion of the normal viral genome has been deleted and can be replaced with a 
new gene or genes to be delivered to target cells. In contrast to chemical and physical 
methods of cellular transfectlon, murine retroviral vectors have proven to be extremely 
efficient fur gene transfer into mammalian cells. Efficiencies as high as 90% have been 
achieved in cultured murine fibroblast cell lines. Murine retroviral vectors differ from 
adenovimses and herpes simplex viral vectors in that retroviruses will only integrate and 
subsequently express their genes in dividing cells. Beeause a defining characteristic of 
malignant tumors is rapid cell division, retroviruses are especially applicable in this 
situation. 
T The Moloney murine leukemia virus 
(MoMLV) is a naturally occurring retrovirus which was serendipifously isolated from 
field rnice;st) its biologicaI characteristics subsequently attracted great scientific interest. 
MoMLV contains a promoter within the 5' long tcrminal repeat (LTR) which regulates the 
transcription of viral R N A . ~ ~  This RNA contains three retroviral gene regions (gag, pol, 
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and env) and the g packaging sequence.52 The gag region encodes core vim1 proteins, the 
pol region encodes the reverse fran~riptase and integrase genes, and the env gene region 
encodes viral coat proteins. Most retroviral vectors also contain an internal promotor 
(such as the SV40 early promoter) to drive transcription of the gene of interest. Retroviral 
vectors commonly include a selectable marker such as the bacterial NeoR gene, which 
encodes NPT I I  (neomycin phosphotransferase II), an enzyme that protects cells from the 
toxic effecb of C418 (a neomycin analog). 
. The .1C, packaging sequence is required for the 
packaging of the viral RNA into an infectious virion. Cell lines have been engineered to 
delete the sequence but retain the gag, pol and env genes. These cells, which produce 
"empty" virions, are termed retroviral packaging cells. The integration of genetically- 
altered MoMLV RNA containing the .ly sequence and the gene(s) of interest (along with 
alterations in the structural genes) into the cellular genome of p a c ~ n g  cells results in the 
production of infectious virions. These cells are called vector producer cells. These VPC 
encapsidate q-positive RNA which is packaged within the virions produced by translation 
I of viral genes. The retroviruses thus produced are replication incompetent by virtue of the 
genetic deletion, and are only infective for a single generation. 
Retrovital infection of cells is a multistep process.53 First, 
h e  retrovirus must bind to the target cell through a receptor on the cell membrane. The 
retrovirus is then internalized. Within the cytoplasm, reverse transcriptase is produced 
from the pol gene and converts the viral RNA genome into a double-stranded DNA 
molecule. Then, the integrase protein (also derived from the pol gene) inserts the 
retroviral genome into one of the cell's chromosomes. lntegrase m y  recognize and bind a 
particular host DNA sequence, so the process may be specific rather than randorn.54 
Typically, only a single integration event occurs in a given cell.% 
S ~ ~ Q L  One safety concern with this system is that vector constructs containing 
inserted genes for use in gene transfer protocols could conceivably recombine with the 
gag, pol and env gene regions of MoMLV, thus generating replication competent wild 
type retrovirus. Because of this risk, the MoMLV vectors have been designed to minimize 
the possibility cjf recombination. Modification of the gag start codon to a stop cocEon and 
elimination of viral sequences needed in trans for the formation of the virus particle 
constitute the major rnodificalions.55 These precautions minimize the potential for the 
manufacture of replication-compeknt virus from producer cells which contain the vector. 
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Other Gene Delivery Methods. The further development of novel gene delivery 
methods is critical to the advancement of gene therapy for malignancies. Efficient gene 
delivery ex vivo into all tumor cells will likely be required for improved tumor 
i mrnunizattion protocols. Likewise, improved gene transfer efficiencies will be critical for 
gene transfer inb  tumor cells in vivo. Currently, the inability to deliver genes to sufficient 
proportions of tumor cells or immune cells is a major impediment to the application of 
gene therapy to cancer. 
& n ~ f i m .  ~ d e n o v i r u s , ~ 6 * 5 7 , ~ ~  a nonintegrating virus, is one of the most 
promising gene delivery methods. Invcstigators have found that various portions of the 
viral genome can be deleted to improve safety. The initial adenoviral vectors have the 
E1A region deleted, wbsch prevents viral replication. The gene of' interest can then be 
cloned into the viral vector genome. Adenoviral vector genornes can wcommdate up to 
about seven kb of foreign DNA and have the advantage of producing titers as high as 1012 
pfu per ml. Adcnoviruses are able to infect and express their genes in a wide host cell 
range with high gene transfer efficiency (over 90%) within the area of injection. 
Adenoviruses enter the cell and disrupt the lyssssmal membrane to escape 
destruction by the cell. The vector remains episomal while expressing its genes; 
integration into the host cell genome rarely occurs. Adeaoviruses do not require celIs to 
be actively dividing at the time of infection for gene expression. Because this virus infects 
a wide variety of tissues, gene transfer by this means is not selective for a specific tissue 
target but is specific to e l l s  expressing the appropriate  receptor^^ The use of tissue- 
specific promoters could theoretically limit gene expression to the target tissue, thereby 
mitigating the effect of transferred genes on normal tissues. These vectors have been 
developed primarily for the treatment of pulmonary disease secondary to cystic fibrosiss. 
. Other viral delivery systems currently under development 
include adeno-associated virus ( A A V ) ~ ,  herpes vipus61, and vaccinia virus62. Integration 
of AAV vectors into host DNA is reported lo be somewhat less efficient than retroviral 
integration, but may be site-specific. Herpes viruses are naturally programmed for the 
persistence in nervous tissue, but the complex regulation of viral replication has made it 
difficult to produce stock vectors. The use of vaccinia virus and other RNA viruses for 
transient expression is also under inveqtigation. 
Nunviral delivery systems are also under active development. 
One nonviral method that has been used in clinical trials is DNA-iiposome 
complexes.@tM Lipsome technology increases the transfeetion efficiency of mammalian 
1 2  
ceI1 s by foreign DNA to higher levels than standard calcium phosphate proeedure~.~5 This 
method also has an dvmtagc in that gene transfer can be accomplished in viva. Receptor- 
mediated DNA delivery can be accomplished by linking DNA to a targeting molecule that 
binds to a specific ceti surface receptor allowing internalization. Such a delivery method 
might allow for the delivery of larger DNA constructs. The gene transfer efficiency of 
these virus-free, nonintegrating methods is high. A variety of other DNA conjugation 
delivery systems are being pursued, but are now at preliminary stages of development. 
Considerations in Gene Delivery. The choice of a gene delivery system for 
tumors is dependent on a number of factors, including the size of the gene, the necessity of 
integration, the desired length of time for gene expression, the Ievel of expression required 
far a therapeutic effect, the nature of the host immune response to the delivery system, and 
the selectivity of the delivery method for the tumor tissue.6e For example, to treat a 
neoplasm with a sensitivity gcne such as the herpes simplex thymidine kinase gene, 
several principles come into play. First, since the object of the therapy is to destroy the 
tumor, permanent genetic alteration of the tissue is not an absolute requirement; once the 
tumor is gone, the gene is no longer needed. Alternatively, to cure a genetic disease, the 
gene would need to be integrated and expressed permanently in the deficient tissue for the 
life of the patient. 
Second, expression of a sensitivity gene need only be at a sufficient level and 
duration to mediate tumor cell destruction. For this purpose, a nonintegrating vector could 
deliver a gene regulated by a cellular promotor that would maximize expression in the 
target tissue. As the tumor cells divide, a nonintegrated gene will be diluted since the 
episomaf vector does not multiply within the cell. For actively dimding tumors treated 
with an episomal vector, repeated gene delivery may be required. The use of vectors that 
are selective for proliferating cells (e.g. retrsviral vectors) or the use of promotors from 
genes expressed in a tissue-specific manner may enhance the effect of genes selectively 
transferred into tumor cells. 
Suicide Gene $trategies$7 Current suicide gene strategies aim to provide a cell 
with a new gene that is toxic itself or that provides an enzyme that can catalyze the 
conversion of a nontoxic prdrug to a toxic form. Thus, targeted cells receive a new 
enzymatic function that sensitizes the ceIi Co a previously nontoxic dmg. The antitumor 
effect is based on the selective gene transfer or expression within tumor cells. For 
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example, retroviral vectors which only will integrate into dividing cells allow for selective 
targeting of thc enzyme to prolikrating tumor cells over nonmitosising normal tissue in 
the same area. Another strategy that might be utiliir~d is to selectively transfer the gene 
for a toxic product without the requirement of converting a prodrug to a n  activc 
compound. If selective transduction of the gene can be done into turnor tissue, then the 
tumor can be preferentially destroyed. Likewise, gene expression of a toxic gene could be 
dependent on the activity of a tumor-specific promotor. Thus, even if  gene delivery is not 
tumor-specific, the toxic gene would not be expressed in the absence of a tumor-specific 
promotor. These ideas represent a few examples as to how suicide genes could be utiJlized 
for anticancer therapy. 
gene is a negative selectable marker or "suicide" gene. HS-tk sensitizes the transduced 
tumor cells to ganciclovir (GCV), an antiviral drug. GCV is a nucleoside analog which 
serves as a substrate for phosphorylation by HS-tk, resulting in a monophosphate (MP) 
form of the drug. Cellular phosphorylases convert this GCV-MP to GCV-triphosphate 
(GC V-TP) which inhi bits primarily viral DNA-dependent-DNA-pol ymerase. The end 
result is the demise of the HS-tk transduced cells. Since the human thymidine kinase 
enzyme, which is normally present in human cells, has very low affinity for GCV. little 
systemic toxicity is observed. 73 
/ 5 - l 3 ~ o r w y h h e  SY&em74 Another negative selection 
marker has been adapted for use as a therapeutic gcne. The bacterial gene cylosine 
deaminase (CD) is found in certain bacteria and fungi and normally deaminates cytosine 
to uracil. It waq recently cloned from E.c& as a gene fragment that encodes a 42 amino 
acid open reading frarne.75 CD catalyzes the conversion of an innocuous compound, 5- 
fluorocytosine (5-FC) to  a highly loxic compound, 5-fluorouracil (5-FU). The 
deamination reaction results in the generation of 5-FU which the cell then converts to 5- 
fluoro-2'-deoxyuridine 5' mono- and triphosphate. These metabolites inhibit both RNA 
and DNA synthesis and cell death becomes imminent. 
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The Bystander ~ f f e c t . ~ ~  A unique feature of the HS-tk/GCV anti-neoplastic 
activity is the observdiotl that not ail the tumor cefls must contain the HS-tk gene in order 
to be hlled by GCV. In vivo, the transplant to mice of a mixed population of tumor cells 
(consisting of as little as ten percent HS-tk positive cells and 90% HS-tk negative cells) 
has frquentty resulted in the regression of the tumor mass upon treatment with ~ C v . 7 7  
The "bystander effect" also occurs in vilro. Various mixtures of HS-tk trrulsduced 
tumor cells and nontmnsduced cells demonstrate complete inhibition of celiular 
proliferation by GCV when only one to 20% of the cell mixture was HS-tk positive. Since 
it is unlikely that 100% of the tumor cells in a patient's neoplasm could be successfully 
modified by genetic manipulation, this bystander effect may prove to be very important 
for successful antitumor responses and could afford gene therapy a greater flexibility as a 
treatment modality, Analysis of firaman melanoma, renal cell carcinoma, and neoplasms 
of breast, lung, and colorwtai tissue reveals that all demonstrate rhe "bystander effect" iin 
viko .78 
The mechanism of this "bystander effect" is not yet completely understood. The 
effect may involve the passage of toxic GCV-TP within HS-tk t r a n s d d  tumor cells into 
adjacent HS-tk negative tumor cells, resulting in their death. This passage may be the 
result of fusion of apptotic vesicles (derived of dying HS-tk-positive cells) with MS-tk- 
negative cel1s,~9 or it may be the result of metabolic coopration, whereby phosphorylated 
GCV is passed from cell to cell via gap junctions.80 Infected cells in vivo could 
potentially initiate an immune response that setectively targets tumor cells.81 A soluble 
"bystander factor," secreted by infected cells and toxic to other tumor cells, has also been 
postulated. Such a factor could be a product encoded by infected cells or a product of 
GCV metabolism. Initial evidence supporting this soluble Eactor model is the finding that 
cell-to-cell contact is not necessary for bystander killing. 82 
Thc bystander effect does not seem to involve generalized, non-specific, cellular 
toxicity, since the overlying skin and other tissues surrounding these HS-tk treated tumors 
are not injured, while the tumors expressing the genes as well as the coincubakd wild-type 
t u m r  cells are completely d e s t r ~ y e d . ~  However, vascular endothelial cells which were 
recruited to nourish the tumor cells are destroyed, which may contribute to the efficacy of 
tumor regression.84 
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Ganciclovir 
Ganciclovir (GCV) is a synthetic acyclic nucleoside analog of 2' deoxyguanosine, 
with a molecular weight of 255 daltons. It is a more potent derivative of acyclovir. GCV 
is the generic name for the chemical 9-(1,3-dihydruxy-2-propoxymethy1)guanine or 
DHPG. GCV is also known by the brand name ~ y t o v e n e . ~ ~  In therapeutic regimens, 
GCV exists in powdered form as a sodium salt (FW = 277.21). En this state, its chemical 
formula is CgH I 2N5-NaO4, 
Utility. GCV is a clinically useful drug which is currently indicated for the 
management of cytomegalovirus (CMV) retinitis in immunocompsomised patients 
(including AIDS patients) and t'or the prevention of CMV disease in transplant recipients. 
The origin of GCV dates back to 1982, when four labs simultaneously r e p o d  in vim 
activity of the compound against GMV.86 GCV has also been used experimentally 
against several other herpes viruses, including h e w s  simplex virus types I and 2 (HSV 1 
and HSV2), Epstein-Barr virus (EBV), and vakcella-zoster virus (VZV).87 
Mechanism. The mechanism of action by which GCV inhibits viral DNA 
synthesis has been studied extensively in vvitro using human cells infected with CMV and 
HSV. After GCV has been transported into the cellular matrix, a viral thymidme kinase 
selectively phosphorylates the compound to GCV monophosphate; this is quickly 
converted to GCV tripfrosphate (GCV-TP) by cellular e n ~ y r n e s . ~  Direct incorporation 
of GCV-TP into viral DNA results in the termination of viral DNA elongation, as GCV- 
TP lacks the 3' hydroxyl group necessary for the addition of another nucleoside 89 A 
second mode by which GCV may inhibit viral DNA synthesis is by competitive 
inhibition of viral DNA poIymerase.90 GCV also inhibits cellular DNA polymerase a ,  
but up to a 20-fold higher concentration is necessary," indicating a preferential 
phosphorylation of CCV in vim-infected cells. 
In vitro, GCV-TP is catabolized slowly, with 60 to 70% of the original level 
remining in the infected cells 18 hours after removal of GCY from the extracellular 
medium." Median effective HSV-inhibitory doses of GCV in several cell lines ranged 
from 0.2 to 3.0 pg/rnl.s In vivn, GCV has a mean plasma half-life of 2.9 + I -  1.3 hours 
and is excreted renallyhg5 A dosage rdnge of 15-135 mg / kg I day for one lo four. weeks 
has been shown to be efficacious in the treatment of CMV in animal rnde1s.B At hgher 
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levels, the clinical toxicity of GCV includes granulocytopenia and thrombucfiogenia; in 
animal studies, CCV was carcinogenic, teratogenic and caused a ~ ~ r n a t c ~ g e n e s i s . ~ ~  
Interleukin- 2 
Interleukin-2 (IL2) is a 15 EeD glycoprotein secreted by activated T-cells that plays 
a central role in the generation of the immune response. IL2 has been called the 
"prototype c y t ~ k i n e , " ~ ~  which reflects its pivotal functionality as well as its early 
discovery. The origins of IL2 date btck to 1965 when a milogenic activity was found in 
the conditioned medium of activated white blood ceHs.95 Years later, it was noted that 
this activity maintained the growth of T - ~ l l s . ~  This discovery fostered the development 
of a quantitative microassay for the activity, which indicated that a single molecule was 
responsible. 97 This molecule is now recognized as IL2. 
Since its inception (and prior to the implementation of a standardized system of 
nomenclature), IL2 has been known by several pseudonyms, including T-cell Growth 
Factor (TCGF), Thymocyte Stimulation Factor (TSF), Thymocyte Mitogenesis Factor 
(TMF), T-cell Replacing Factor (TRF), and Killer Helper Factor ( K H P ) . ~ ~  The variety of 
these early names, which were generalfy assigned on the basis of observed in vifro 
activity, is testament to IL2's wide-ranging activities. 
Interleukin-2 Activities. The pleiotropic, receptor-mediated effects of 
interleukin-2 have been well-characterized.. J L 2  promotes the proliferation of T (and B) 
lymphocytes and stimulates other cytotoxie cell populations and macrophages. These 
activities will be expanded upon below. 
By stimulating the expamion of selected T- and B- 
cell clones, IL2 largely determines the magnitude and pace of the antigen-specific 
immune response.* IL2 is the primary regulator of the T-cell cycle, and is required for 
the progression from Go to ~ ~ 1 0 0 .  Moreover, progression of the T lymphocyte cell cycle 
has been shown to be solely dependent o n  three factors: IL2 concentration, EL2 receptor 
density, and the duration of the IL2 I IL2-recept~r interaction lol 
IL2 is also essential for the augmenting the generation of major T-cell 
subpopulations, notably CD4+ (helper) and CD8+ (cytotoxic) T-cells with increased 
cytolytic activityl02. It ha5 been shown that the mechanism behind this boosted cytolysis 
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is that 1L2 augments the expression of the genes encoding the l y tic molecules involved in 
cytolysis. 
Exposure to IL2 in vlrm results in the production and maintenance of' mature 
cytotoxic T-cells from terminally differentiated precursors. This finding was later 
corroborated by the in v i m  observation that IL2 can reconstitute a normal response from 
an acquired ~mmunodef'icient state 105 
IL2 also prhcipates in the promotion of B-cell function. IL2 makes possible the 
production of IgM pentamers by stimulating expression of J chain mRNA; it also 
potentiates the switch from the membrane form to the secretory form of y heavy 
chains,Ifi thus enhancing B-cell vigilance. 
IL2 is also an important stimulator of the 
. IL2 causes the activation of phagocytic 
leukocytes, such as neutrophils and monocytes. lcn Exposure of macrophages to IL2 
results in the induction of macrophage-mediated cytotoxicity,lm as well as stimulation of 
antibody-dependent cell-mediated cytotoxicity.109 Additionally, this cytokine 
participates in the tumoricidal activation of peritoneal macrophages."0 
Interleukin-2 also induces the proliferation and e n h a n d  
response of natural, killer (NK) cells1 11 and lymphokine activated killer (LAK) cells. 112 
NK cells are large granular lymphocytes which participate in nonadaptive, nan-MHC 
restricted cell-mediated cytotoxieity.lD in vvitra and in vivo evidence shows that NK cells 
are intimately involved in the destruction of tumor cells and the prevention of 
metastasis."'" NK cells, which constitute about 3.6% of all lymphmytes.ll5 are unique 
in that they express 112-receptors constitutively and secrete IL2. Thus, these cells are 
always immediately IL2-reactive and have the potential to be self-regulatory. A 
functional thymus is not required for the maturation of NK cells; rather, these cells are 
believed to originate and differentiate in the bone marrow.I17 The response of NK cells 
is of particular interest in that these cells constitute one of the few immunological 
weapons available in the limited arsenal of the athymic nude mouse. In fact, athymic 
rodents have been shown to have more pronounced NK activity than do their euthymic 
l i t temtes.  118 LAK cells are non-MHC restricted cells which arise from peripheral blood 
lymphocytes after selection with IL2.119 LAK cells are capable of lysing NK-resistant 
tumor cells, with minimal toxicity to normal cells. 120 
The cascade-like secondary effects of lL2 are also of great 
importance. IU serves as an initiator molecule, which induces immune competent cells 
18 
to significantly alter their cytokine profiles. NK cells are stirnulaled by IL2 to secrete 
interferon-y, GM-CSF, and TNF-a; activated T- and B-lymphocytes are stimulated to 
secrete IL-lB, IL-4, IE-5, and 1 ~ - 6 . ~ 8  These secondary cytokines are likely in turn to 
mediate potent immunoiogic and regulatory effects. For example, interferon induces 
expression of IL2 receptor alpha chain. 121 
Structure. The IL2 gene has been cloned and characterized at both the 
complimentary-DNA and geaomic levels. Primary IL2 mRNA transcripts consist of four 
exons separated by one short and two longer introns. 122 The three-dimensional structure 
has been solved to a resolution of three angstroms. la The translated protein consists of 
153 residues, with six alpha helices arranged in antiparallel fashion. 124 Elimination of the 
single disulfide bond greatly reduces IL2 activity, as do small changes in the primary or 
secondary structure. 
IL2 Receptor. Interaction of IL2 with its receptor (IL2R) is a necessary trigger 
for biologicd activity. The receptor consists of three distinct chains, each with about 215 
amino acids in the external domain.98 The alpha chain is 55 kD, anchored by f 3 
cytoplasmic residues. 126 The 75 kD beta chain has 286 cytoplas~llic residues,l27 and the 
bashful gamma chain, only recently coaxed horn hiding, is now known to be 64 kD with 
86 internal r e s i d ~ e s . 1 ~ ~  These three chains, which constitute the IL2 binding site, 
cooperate kinetically to glve a very high affinity ligand-receptor interaction (10-11 
rnol/L);129 the affinity plummets when specific antibodies block any one of the three 
peptide chains. "5 
Clinical Immunoiherapy. Use of IL2 as a therapeutic agent has been 
championed for years. Its role as an immune stimulant has been attractive in 
expenmental trealment of immwuodeficiency and infectious disease, and also as a vaccine 
adjuvant 98 IL2 has been OF particular interest in protocols fur cancer imrnunotherapy. 
The goals of such Lherapy include the local release of low levels of IL2 capable of 
stimulating the immune system, activation of cytotoxic T-cells specifically directed 
against tumor cell antigens, and generation of immunological memory. 120 
In immune-competent mice, injection of tumor cells transduced with IL2 has 
resulted in the reduction of turnorigenicity and the development of protective 
immunity. "0 Thus far in human clinical trials, IL2 has been used to treat malignant 
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melanoma, breast carcinoma, renal cell ca~cinoma,'3' and acute leukemia.1" To date, 
administration of this cytokine appears to have some efficacy in these settings: the 
combined response rate has been a h u s  20% (with five percent experiencing a complete 
rernission.fg& However, results have somewhat tarnished by unpredictable responses and 
the onset of IL2 toxicity. 
Toxicity. IL2 toxicity has been shown to be dose-dependent; the maximum- 
tolerated intravenous dose in humans is 10 mg as an immediate bolus, or 1 rng per hour 
over a 24 hour period. 133 At excess levels, toxicity is manifested in the form of fever, 
rigors, general malaise, myatgia, nausea, vomiting, vascular leakage syndrome, 
hypotension, and shwk.134 In some patients, IL2 has also been shown to produce a 
delayed-type hypersensitivity in the absence of antigen. 135 
Parameters of IL2 Administration, While toxic levels of iL2 have been 
defined, clinical agreement of safe yet biologically relevant levels remains more 
ambiguous. Clinicians generally report IL2 levels in terns of units, which is a derivative 
measure of functionality. One unit is defined as the "reciprocal of one final dilution of 
IL2 giving 508 of the activity of a standard 1L2 preparation, determined by 3H thymidine 
incorporation."136 This delinition implies that the unit is a relative measure that is not 
read~ly eonvefled into a quantitative figure. However, a level of two units per ml has 
been reported to support growth of T-cells in culture 137. 
In addition to the dose-dependent parameters, response to IL2 has been shown to 
be time-dependent. At minimum, a six-how incubation with lL2 is needed to induce an 
increase in the proliferation of human peripheral blood mononuclear cells, and growth 
continues to increase with time. 101 The same source reports that an IL2 concentration of 
100 picomolar (pM) is sufficient to saturate existing IL2 receptors, but a significant 
proliferative effect is seen with as little rn 25 pM. It has k e n  reported that 100 pkl IL2 is 
sufficient in viaro to promote the proliferation of the ten percent subpopulation of 1VK 
cells that express high-affinity fL2 receptors; a 100-fold increase (10 nM) in IL2 
cclmncentration is necessary to stimulate the remaining 90% of NK cells, which have lower 
affinity receptors. 138 
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The Athyrnic (Nude) Mouse 
In 1968, it was reported that the nude mouse mutant (BALBtc, ndnu ) has a 
congenital absence of the thymus, and thus lacks T - l y r n p h o c y t e ~ . ~ ~ ~  This discovery 
suggested that chis mouse strain was deficient iu cell-mediated immunity. Nude is a 
mutant allele of the nude locus of the VII linkage group (chromosome 1 1).14 The allelic 
delelion responsible for the loss of immunity also renders these mice hairless, which 
gives the term "nude" a double-entendre. Subsequently, it was reported that a human 
colon carcinoma grew as a xenograft when transplanted subcutaneously to nude rnice.l4l 
Since thcn, the nude mouse has become an important modcf for studying hun~an 
neoplasms and treatment modalities. 
The rationale for employing the nude mouse model in cancer research is based on 
the supposition that transplanted human xenografts retain the characteristics of the 
original tumors. Comparative studies of original and transplanted tumors have shown 
that the chromosome pattern, DNA content, and histology of the tumor remains 
unchanged. 142~1~3 Moreover, the sensitivity of human tumor xenografts to therapeutic 
regimens is reported to correlate to experience of cli~iical treatment of the same tumor 
entity. 1 4  
Although the nude mice lack functionally mature T Iymphocytes, they are not 
completely immunodeficient. These mice show a nearly norm1 response to T-cell- 
independent antigens.145 B-cell gmwth and differentiation is not depressed in these 
animals, and thus high titers of natural antibodies may be present, which can rwct with 
tumor cells.l& However, the lack of helper T cells would be expected to alter the 
antibody response to antigens. Secondly, tumoiicidal macrophages can be isolated from 
nude rnice,147 which can contribute to the destruction and clearance of tumor cells. 
Perhaps most importantly, nude mice exhibit high levels of NK cell activity. 148 All 
three of these effector mechanisms contribute to the natural resistance of nude mice to 
transplanted tumors. and may account for some of the differences observed in the growth 
patterns of different tumor cell lines, as well as the individual vasiation seen in mice 
receiving identieat imp1a.nts. 
Nude mice are especially susceptible to environment& contaminants and 
infectious disease. Under standard labratory conditions, these animals fail to thrive and 
have an average survival time of only 14-30 days. However, t h s  survival time can be 
increaqed to over two years by maintaining the mice under gem-free conditions.149 
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MATERIALS AND METHODS 
Veetor Construction 
The retroviral constructs of all vectors used in these studies were derived from the 
Moloney Murine Leukemia Virus (MoMLV). The STK vector, obtained from F. 
Moolten (Veterans Memorial Hospital, Boston, MA) consists of the following construct: 
LTR--N~OR--SV~--TK--LTR.~~~ This vector contains the herpes simplex type 1 
thymidine kinase gene, driven internaily by the simian virus-40 (SV40) early promotor. 
The vector is flanked by long terminal repeat (LTR) sequences; the 5' LTR is the 
promotor for the neomycin phosphotransferase I1 (NeoR) gene, which confers resistance 
to the neomycin analog, G418 (Gibco, Grand Island, NY). 
The IL-2 vector (ClI2SvNa), obtained from Genetic Therapy, Iac.(Gaithemburg 
MD), has a construct of LTR-IL2-SVN-NeoR-LTR. The open-reading frame of' the 
human interleukin-2 gene is located downstream of the 5' LTR sequence, and uses this 
sequence as its promotor. The SV40 early promotor serves as an internal promotor for 
the NeoR gene. 
The BAG vector (GlBgSvNa), also obtained from Genetic Therapy Inca, consists 
of the following construct: LTR-BAG-SV40-NeoR-LTR. BAG is the designation for an 
Escherichia coli B-galactosidase gene which was excised from pBR322 plasmid and 
ligated into the retroviral backbone. 
A11 three vectors are individually packaged by the amphotrophic retroviral vector 
producer cell line PA317, derived from NlH 3T3 fibroblasts (ATCC CRL# 6473). STK 
vpe are reported to generate a supernatant with a titer of 5-10 x lo6 retrovira! vector 
particles per ml. 1L2 vpc are reported to generate a supernatant with a titer of 5-10 x 106 
particles/ml. BAG vpc are reported-to generate a supernatant with a relatively lower dter 
of 1-5 x lo6 particleslml. The titer of each vpc is pertinent to the transduction efficiency 
of target cells. 
Cell Culture 
Four human osteosarcoma cell lines ( M N N G  CRL# 1547; MG63: CRL# 1427; 
TE85: CRL# 1543; 6292: CRE# 1423) were obtained from American Type Culture 
Collection (Rockville, MD). A fifth osteosarcorna cell line (MLM) was derived at h e  
Human Gene Therapy Research Institute (HGTRI; Des Moines. IA) from a lung 
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metastasis induced in an athymic mouse following orthotopic implantation to the tibia1 
plateau of MNNG cells. 
All cells were grown in complete media, consisting of 86% Dulbcco's Modified 
Eagle Medium (DMEM), with ten percent (by volume) heat-inactivated fetal bovine 
serum (The Salzrnan Corporation: Davenport, IA), and additionally 2 m M  L-glutamine, 
50 ranitdm1 penicillin, 50 pglml streptomycin, and 2.5 pgirnl fungizone. (Except as 
noted, all of these tissue culture reagent were obtained from Quality Biological Inc.) 
Cells were grown in Nunclon (Denmark) tissue culture flasks (175 cm2 or 80 
crn2)* and maintained in a Steri-cult 200 Incubator (Forma Scientific; Marietta OH) at 
37OC, 95% humidity, and 5% C02. Tissue culturing was always performed under sterile 
conditions in a laminar flow hood (Forrna Scientific). 
Cells were passaged in the foPlowing manner: when confluent monolayers were 
achieved, the cells were washed in 10 ml Hank's balanced salt solution (PFBSS; QBI) then 
exposed to trypsin-ethylenediamine-tetra-acetic acid (0.05%; QBI) at the minimal volume 
necessary to cover the bottom of the flask (4 rnl for T-175 flasks and 2 rnl for T-80 
flasks). A five minute incubation at 370C was sufficient to induce loss of cellular 
adherence. The cells were harvested by resuspending in complete media (10 ml), mixing 
thoroughly by agitation with a pipette and transferring to a sterile container (generally 50 
ml Falcon centrifuge tubes). Washing the inside of the flask Owice with HBSS (10 ml) 
completed the harvesting process. Harvested cells wcre counted with a hemocytometer, 
centrifuged at 1503 rpm for 5 minutes. and replated at dilutions ranging from 1:2 to 1:20, 
as needed. Mcdium was changed twice weekly, depending on the number of cells plated. 
Cells used for injection into animals were resuspended in serum-free DMEM at 
the desired concentration, typically 2x107 to 108 cells per ml. Cells not required for 
immediate use were frozen by resuspending in 70% complete media, 20% fetal bovine 
serum. and 10% dimethylsulfoxide (DMSO; ATCC) at a concentration of 107 cells per 
mI. The suspension was aliquotted into Coming cryovials (two ml size; Corning, NY) 
and frozen sequentially at -200C, -700C, and - 1 W C  over a period of 48 hours. 
CelI Counts 
Enumeration of cells was performed in duplicate with a SPotlite hemocytometer. 
Two identical volumes (50 yl) of cell-containing media were transferred to each of two 
chambers of a 96 well plate into an equal volume of Trypan Blue solution (0.4%; Sigma: 
St, Louis. MO). A coverslip wag placed on the hemocytometer, and the mix tms  were 
23 
pipetted onto opposite sides. The volumes of original cell suspensions were diluted so as 
to have an estimated 200-400 cells per counting ficld. A total of eight fields were 
counted, and the results were averaged and adjusted according to the dilution factor to 
arrive at the totd cell count. 
Cellular Transduction with Retmvirat Vectors 
Human osteosarcorna cells (105) were plated in  triplicate in a 6-1~ell plate in 5 rnl 
of complete media and allowed to attach overnight. The following morning, the 
supernatant (25 ml) from confluent T-175 em2 Nunc fiasks of vector-producing cell lines 
(STK, IL2, or BAG) was removed. After the addition of protarnine (5 pglrnl; Elkins- 
Sinn, Inc., Cherry Hill, NJ), the supernatant was passed through a 10 ml syringe (Becton- 
Dickinson) fitted with a 0.22 micron filter (PCC Scientifics, Gaithersburg, MD). 
Protarnine, a polycation, is added to alter the eel1 surface charge to improve vector: cell- 
receptor binding. The filtered suprna2aatlprotannine was then applied to the -get cells 
(5 ml per well.) This process was performed six times at intervals of approximately 12 
hours. The morning following the sixth transfer, supernatants were aspirated from the 
osteosarcoma cells and replaced with cornpEele medium containing the antibiotic G418 
(neomycin) at 1 mg/ml (active drug concentration: Gibco). Cells which had been 
successfully transduced with xhe NeoR gene were able lo survive the ten to 14 day 
selection process. G418 resulted in the destruction of a substa3ltial proportion of the 
tumor cells, suggesting a gene transfer elficiency of less than 10%. 
Cellular Proliferatbn Assay 
Cells at passage five to 15 were harvested and counted. One million cells were 
placed In a T-75 flask, and the time was noted. The cells were examined daily; when 
90% confluency was achieved (usually 72-96 hours), cells were harvested and counted 
quantitatively in duplicate. Generation time was calculated according to the standard 
equation for logarithmic growth: t gen = 0.301 ti (log Xt -6), where t gen = generation 
time, t = incubation time, Xt = final cell count, and 6 = l 0 ~ ~ ~ ( 1 0 ~ ) .  
In Vitro Bystander Asmy 
Four different mixtures of vector and target cells were made. The first invoJved 
STK-transduced cells as the vector and wild type celfs as the target The second involved 
a combination of equal amounts of STK- and IL2-transduced cells as the vector, and wild 
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type cells as the target. The third group involved IL2-transduced cells as the vector and 
wild type cells as  he target, and the fourth used STK-trmsdueed cells as the vector and 
112-transduced cells as the target. For each of the four groups, a total of eight mixtures 
were plated in triplicate in 96-well plates: 100% vector cells. 50% vector and 50% 'orget, 
25% vector and 75% target, 10% vector and 90% target, 5% vector and 95% target, 2% 
vector and 98% target, 1% vector and 99% target, and 100% target cells. See Table I 
below. 
Table 1 : 96-Well Plate Formatted tor Bystaader Assay 
STK: NV I STWIL2 : NV I IL2: NV I STK: IL2 
Wild type, STK-transduced, and fL-2 transduced cells were harvested, and diluted 
in complete media to a concentration of 5x104 cells per ml. Appropriate mixtures of 
cells were made in tripiicate by volume. Each well of the plate had a final volume of 0.2 
ml, with a total of 1 o4 cells per well in %-well flat bottom plates, once for each cell fine.. 
'he plates were incubated at 37OC over nigh^ to allow attachment o l  cells. The next 
morning, GCV (Canciclovir; Syntex Laboratories Inc., Palo Alto, CA) was added as 5 
p g / d  in HBSS, and the plate was incubated for 48 hours. Four hours prior to harvest, 5 
pCu/ml tritiated thymidine ( r n e t h ~ ~ l - ~ ~ ,  DuPont 1 Nen) was added to each well (50 pl of 
20 pCu/rnl stock). During lhis incubation, actively dividing cells incorporated the 
radiolabel into replicated DNA strands. After this time, media from each well was 
aspirated and disposed according to Radiation Safety Guidelines. Next, each well was 
rinsed once in  EBSS (100 pl) to remove dead cells and unincor d label. Next, 0.05% 
trypsin (50 pl) was added, and after an incubation period of ten minutes at 37OC, the cells 
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were collected onto a filter strip by a cell harvester (Tomtec Inc., Orange, CT). 
Radioactivity was measured by a Beta Plate Reader (LKB Wallac, Gaithersburg, MD), 
and is expressed as the mean DPM (disintegrations per minute) of triplicate wells. 
Comparisons were made between radioactivity of target cells alone versus radioactivity 
with each coincubation percentage of transduced cells. 
This assay was repeated for the MNNG line using a more rigorous experimental 
design with twelve replicates per treatment group to confirm the earlier results. The 
percentages of transduccd cells were designed as a gwmetric progression (i.e., 1, 2, 4, 8, 
16,32,64) to readily afford the evaluation of HS-tk / ZL2 synergy. Control wells for each 
cell line without GCV and for cell-free complete media were included. 
CCV Sensitivity Assay 
Each cell type (wild type, STK-transduced and lL2-transduced) from a given 
osteosarcorna was harvest and diluted to 5x104 cells/ml media as described above. Each 
cell type was plated in 12 wells of a 96 well plate (104 cetls in 0.2 ml). After incubating 
overnight, GCV was added in 20 pl HBSS: three wells of each sell type received 2 
pglml, three wells received 5 pg/ml, and three received 10 yglml as the final 
concentration. The remaining three wells of each cell type received 20pl of HBSS and no 
GCV. After a 44-hour incubation, the cells were radiolabeled, harvested, and meamred 
for radioactivity as above. 
X-Gal Staining 
To evaluate the in vitro and in viva transduction efficiency in cells of the BAG 
gene, B-galactosidase expression was detected using an X-Gal histochemical stain. 151.152 
Cells which had been passaged at least live times and which putatively contained the 
BAG gene due to 6418 resistance (i.e.. all five BAG transduced osteosarcorna lines and 
BAG v p )  were harvested and plated (1x104 cells per well in 2 ml media) in triplicate in 
six-well plates (Corning). The plates werc incubated overnight at 370C. The next day, 
the media was removed and replaced with a fixative solution (0.05% glutaraldehyde, 2 
ml: QBI). The cells werc fixed at room temperature Tor 15 minutes. Next, the fixative 
was aspirated to an appropriate container, and the cells were rinsed thrce times in HBSS. 
The second rinse was applied for about ten minutes to minimize the l i k e l i h d  of leaving 
residual fixative. Next, X-gal solution (40 tnl) was made by addmg X-gal / Ibrom04-  
chloro-3-indoyI-l3-D-galacbsidase. 40 mg in DMSO (1 ml)l to  he Reaction Mixture 139 
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ml of 5.0 mM K3Fe(CNg) = potassium ferricyanide, 5.0 mM KqFE(CN63.3H20 = 
potassium ferrocyanidc, and 2.0 mM MgC12 in PBSJ. Because X-Gal is photosensitive, 
carc was taken to avoid prolonged or direct exposure to light, Sufficient solution to cover 
the cells (1 ml) ~vas then added. The plates were incubated overnight at 370C. 
Staining with X-Gal turns B-galactosidase-expressing cells blue when an indolyl 
is liberated from X-Gal by the adion of IJ-galactosida~e, and subsequent oxidation and 
self-coupling forms an indigo blue derivative. A gradation from colorless LO deep blue 
was seen, indicating a range in cellular expression. The vector-contarning cells can thus 
be discriminated from unmodified cells and enumerated with light microscopy. Cells 
were scored as positive (strongly or moderately blue), and negative (no color change), 
and at least 500 cells of each line were visualized and scored. Control cells (each of the 
five wild type osteosarcornas as well as STK and I t 2  vpe) were also collected and 
stained. All cells were negative for expression of the BAG gene. 
ELlSA b y  
An I t2  Immunoassay Kit was obtained from Pharmacia Biotech Inc. (Piscatawa, 
NJ). The kit consisted of an IL2 Microliter Plate with 96 removable polystyrene 
microtiter wells coated with a rnurine monoclonal antibody against It2, IL2 standard (10 
ng), Assay Diluent RDlA (11 ml), Calibrator Diluents RD5 and DRD6E (21 ml each), 
Wash Buffer Concentrate (26 ml of 25x strength), Color Reagents A and B (12.5 rnl each 
of hydrogen peroxide and chrotnogen (tetramethyIbenzidine), a d  Stop Solution (6 ml of 
2N H2SO4). 
To perform the ELISA, Assay Diluent RDlA (100pI) was added to each well to 
be used, followed by cellular supernatants and standard solutions (100pl). Supernatants 
were coliected and centrifuged immediately before use. IL2 standards were prepared by 
making six serial doubting dilutions from a 2000 pglml stock. All samples and standards 
were assayed in duplicate when possible. The microtiter plate was mixed gently and 
incubated at m m  temperature for two hours. Next, each well was vacuum aspirated and 
washed three times with Wash Buffer (400~1). IL2 conjugate (200~1) was added, and the 
plate was again incubated for two hours at room temperature. The aspirationlwash steps 
were then performed. N e ~ t ,  Substrate Solution (200~1) was added to each well. After a 
20 minute room-temperature incubation, Stop Solution (50~1)  was added to each well, 
and the color change was measured using a spectrophotometer (Hewlett-Packard) set at 
450 nm. Data are expressed as picograms of IL2 produced per I @ cells per day. 
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Nude Mice 
Congenitally athymic female nude mice (BALBic, ndnu ) were obtained from 
Harlan-Spmgue Dawley and housed in laminar flow cabinets in the nude mouse room at 
HCTRI. Ail mice were afforded autwlavd chow and water ad libitum throughout their 
stay and were kept for at bast one week before any experimentai manipulation. Three to 
six mice were housed per cage, and the mice were monitored daily by investigators and 
animal facility staff. 
Injectfons. Mice were restrained by grasping the scruff of the neck between the 
thumb and index finger, then holding the tail with the fourth finger of the same hand. All 
injections were done with one, five, or ten rnl syringes fitted with 27 gauge hypodermic 
needles (Becton-Dickinson). Injections of cells, diluted to thc appropriate concentration 
rn a volume of 0.05 to 0.2 ml HBSS, were done subcutaneously halfway between the 
diaphragm and pubic symphysis, using at least a 0.5 cm injection tract. The formalion of 
a bleb was the criterion for a successful injection. Inlratibial injection was done after 
effecting anesthesia by momentarily placing the nose of the mouse in a 50 ml conical 
tube containing a gauze soaked in Metofane (mcthoxyfluorane: Pitman-Moore, Inc., 
Washington Crossing, NJ). The shaft of the bone was penetrated through the tibia1 
tuberosity I cm into the shaft by using the needle like a drill. 
GCV Treatment, CCV (3 mg in I ml HBSS) was injected intraperitoneally; 
GCV injections were done twice daily at ten ta 14 hour intervals for a period of 12 days. 
Nlice experiencing toxic effects were given reduced doses (2.5 rnglml) for the remainder 
of the treatment period. 
Assessment. Mice were evaluated daily for tumor size using calipers. Mice with 
tumors exceeding 20 mtn by 20 mm, as well as mice having completed fallow-up 
evaluation, were euthanized with C02 or by cervicd dislocation. 
Preparation of T b u e  for Histology 
Tissue samples were obtained by sterile dissection, then placcd in a solution of 
5% formaldehyde. Specimens were then stored at room temperature. Tissue sectioning 
and hcrnotoxl y in and emin staining were done contractually off-si le. 
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Tumor Harvest 
Afkr euthanasia, each tumor was isolated in sterile fashion in a laminar ilow hood 
using a scalpel, then minced to fine pieces in a petri dish, suspended in 15 mi complete 
media, and transferred to a SO ml conical centrifuge tube. Filtcred tumor digestion media 
(15 ml, consisting of collagenase (1 mgiml). DNase (0.1 rnglml), and hyaluronidase (15 
unitslml) in H B S S :  all from Sigma) was added. The tube was then agitated horizc)ntally 
at a moderate speed for 30 minutes on a Red Rotor shaker (Hoefer Scientific 
Incorporated, San Francisco CA), then ailowed to stand vedically for two minutes to let 
large particles settle. The liquid (excluding settled particles) was then transferred to a 
clean tube and centrifuged at 1500 rpm for five minutes. F'elleted cells were resuspended 
in media, counted and cultured in the standard fashion. 
Statistical Analysis 
Significance of results was calculated at 95% confidence limits using Student's t 
distribution, according to the equation t = (X - p) / (s / (1110.5 ) with n-l  degrees of 
freedom, where t = confidence limits, X = mean experimental value, p = interval of 
significance, s = standard deviation, and n = number of replicates. h4icrosoft Excel was 
used as a tool to determine standard deviation and mean values 
RESULTS 
Five human osteosarcoma cell lines (MNNG, MLM, TE85, MG63, and G292) 
were studied, and each of these lines was stabfy and separately transduced (via retroviral 
vectors) with three recombinant genes: Herpes simplex type 1 thymidine lrinase (STK), 
human interleukin 2 (It2). and bacterial 13-galactosidase (BAG). Throughout this text, 
the cell lines thus generated are designated by the parental abbreviation followed 
parenthetical1 y by the vector The designation (NV) indicates the "no-vector" wild type 
tumor cell line. Expression of gene products from a11 cell tines was determined 
empirically. Each cell type was studied as to prolii'eration rate, GCV sensitivity, and the 
potential for bystander effect. Throughout this text, the term "proliferationt~s used 
interchangeably with "thymidine-incorporation" for the sake of simplicity; in the strictest 
sense, the extent of thymidme incorporation is only directly proportional to the level of 
proliferation, in that cells which incurprate the radiolabel are both the original, parental 
cells and the products of mulliple division cycles. 
Assays for transductton of functional vectors. A functional assay for GCV 
sensitivity was performed on all STK-transduced lines surviving G418 selection (fig. 1) 
The GCV-mediated inlubitioa was dose-dependent, and had only a small inhibitory effect 
on control (NV) cells. Four of the five cell lines showed high susceptibility to low Ievels 
of GCV; in each case, at least 98% decrease in proliferation (as compared with confrol 
cells of the same type receiving no GCV) was seen at 2 pg/ml GCV. At higher levels of 
GCV (10 pglml), the percent decrease in proliferation ranged from 99.4 to 99.8%. The 
fifth line ((3292) showed less sensitivity compared to the other four lines, with 83.7% 
inhibition at 2 pglml, up to 93.7% at 10 pgJml. The wild type (NV) and IL2-transducal 
lines, tested along with the STK-transduced lines, showed slight susceptibility to CCV 
(addressed further below). 
FIGURE 1: GCV Sensitivity of Five Osteosarcorna Cell 
Lines Transduced with the STK Vector 
Cell Line 
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An IL2 ELISA was performed on supernants from confluent flasks of all IL2 
transduced lines. All five lines, as well as: IL2 vector producer cells, tested positive for 
production of antibody-recognizable IL2 (fig. 2). Two IL2-transduced lines (MNNG and 
W M )  showed very high prductian (7438 and 57.16 pg / 105 cells / day respectively), 
Three lines (IL2 vpc, M663, and TE85) showed moderately high levels of IL2 
production (31.32, 24.06, 20.44 pg / 105 cells / day respectively). The other cell line, 
G292, showed relatively low IL2 production (8.23 pg / 105 cells / day). All non- IL2- 
transduced lines (including STK and BAG vpc) were also &seed;   he absorbance readings 
for these lines were not significantly different (p > 0.05) from the background level (i.e., 
less than 0.3 15 pg I lo5 cells / day). 
X-Gal staining was performed on all BAG-transduced lines and the BAG vpc (fig 
3). Four of the transduced osteosarcoma lines showed a strong majority of positively 
stained cells (MNNG: 79.1%; MLM: 85.4%; T B 5 :  76.8%; MG63: 89,8%), closely 
approaching the percent positive BAG vpc (91.1 %). For the 6292 (BAG) line, Leas than 
half (48.6%) of cells stained positively. Non-trmsduced iines and STK and IL2 vpc were 
completely negative. 
F1GURE 2: ELISA-Confirmed Human-Speeif ic 
lL2 Production by Five lL2-Transduced 
Osteasarcoma Cell Lines and 
Murine IL2 Vpc 
112 vpc MNNG MLM TE85 MG63 '3292 
Cell Line 
FIGURE 3: 8-Galactosidase Expression as Determined 
by X-Gal Staining of BAG-Transduced, 
G418-Selected Osteosarcorna Cells and 
Murine BAG Vpc 
0 
MNNG PALM TE85 M063 G292 BAG vpc 
Cell Line 
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Cellular Proliferation Assay. Table 1 shows the expcrimenk.ally determined 
generation times far each of the 23 cell lines used in this project. 
TABLE 2: Growth Rates for Twenty Osteasarcoma Lines and Three 
Vector-Producer Cell Lines 
-- 
CELL LINE GEN. TIME CELL LINE GEN. TIME 
(HOURS) (HOURS) 
MNNG(NV) 24.9 MG63 (NV) 39.1 
MNNG (STK) 26.9 MG63 (STK) 50.7 
MhrNG (IL2) 26.9 MG63 (I L2) 43.1 
MNNG (BAG) 28.5 MG63(BAG) 23.2 
MLM (NV) 27.0 
MLM (STK) 23.2 
MLM (IL2) 31.4 
MLh4 (I3 AG) 23.0 
G292 (NV) 81.0 
43292 (STK) 81 $6 
G292 (IL2) 86.7 
G292 (BAG) 5 1.9 
TI35  (NV) 24.7 STK VPC 26.4 
TEss (STK) 20.3 IL2 VPC 24.3 
TI35  (IL2) 23.4 BAG VPC 194 
Ti335 (BAG) 24.6 
Doubling times ranged from a minimum of 19.4 hours (BAG vpc) to a maxtrnurn 
of 86.7 hours (G292 BAG). Three of the five osteosarcoma lines showed a narrow range 
of variation in growth time. Generation times for the MNNG line showed a 12.5% range, 
from 24.9 hours (NV) to 28.5 hours (BAG). The h4LM line showed a 26.8% variation 
(23.0 hours for the BAG-ttansduced line, to 31.4 hours for the lL2-transduced line.) 
Generation times for the TE85 line ranged from 20.3 hours (STK) to 24.7 hours (WV). or 
17.98. The other two osteosarcoma lines showed greater variation. A 54.3% variation 
was seen between the different MG63 lines (23.2 hours for the BAG-rransduced line to 
50.7 hours for the STK-transduced line). A range of 40.1% was observed for the 6292 
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line (51.9 hours for the BAG-transduced line to 86.7 hours for rhe IE2-transduced line. 
The (3292 celis showed a significantly {p < 0.05) slower doubling rate compared to the 
other cells lines. 
Re troviral -mediated transduction wlth each of the three genes (STK, IL2, and 
BAG) did exert an effect on the generation time of each of the five human osteosarcoma 
tumor cell lines; however, the effect was not uniform lor each geae. STK-transduction 
resulted in a significantly slower generation time in two of the five lines (MG63: 29.5%; 
MNNG: 7.8%). In two lines, transduction with the STK gene resulted in cells with a 
faster generation time (TE85: 17.9%; MLM: 14.3%). IL2-transduction resulted in 
slower growth in four lines (MLM: 15.9%; M663: 10.2%; MNNG: 7.8%; and 6292: 
7.1%). BAG-transduction resulted in faster growth in three lines ( M W :  40.8%; G292: 
35.9%; MLM: 15.2%). In the MNNG line, BAG transduction resulted in a 12.5% slower 
generation times. For cell lines not noted above, transduciion resuIted in no significant 
diference in generation time. 
Generation times were also determined for the three vector producer cell lines. 
While they were comparable, the BAG vpc replicated the most rapidly of' these lines, and 
was the fastest growing cell line overall, with a doubling time of 19.4 hours. The IL2 vpc 
had a generation time of 24.3 hours, and the STK vpc doubled every 26.4 hours. 
GCV Sensitivity Assay. (Fig 1). EaGh cell type within each osteosarcorna line 
was incubated in three different GCV concentrations (0, 2, 5, and 10 pglml) for 48 hours. 
Only cells insensitive to GCV are expected to survive this challenge, Four hours prior to 
harvest, the cells were exposed to tritiated thymidine. Actively dividing cells incorporate 
the radiolabel during their replicative processes. Thus, the level of radioactivity 
(measured as disintegrations per minute or DPM) is proportional to the number of cells 
surviving incubation wirh CCV. The DPM fbr the GCV-negative wells were used as the 
control for comparison within each cell type. In four of the five osteosarcoma lines, 
GCV-mediated inhibition at 10 pglml exceeded 99.4% for the STK-transduced lines. 
Thus, susceptibility to GCV was acquired by the tmnsdueed cells, confirming that these 
tumor cells express functional HS-tk. Wild-type lines did show some sensitivity to GCV 
with a decrease in growth rate ranging from 35.9% (C292) to 68.4% (MLM) at the 
highest concentration of GCV. 
In two of the five osteosarcoma lines (MLM, and G292), transduction with IL2 
induced a protective effect; i.e., these cells showed an increased level of survival as 
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compared with the corresponding NV lines. In the other three lines, susceptibility of IL2- 
transduced cells to GCV was not significantly different to that seen in the non-transduced 
cells. Table 2 below shows the percent inhibition (compared with control cells receiving 
no GCV) for each cell line at the highest concentration of GCV tested. The complete 
results of these assays (expressed in DPM far each cell line at all tested leveis of CCV) 
are depicted below (figs 4-8). 
FIGURE 4: In Vitro GCV Sensitivity Assay - 
MNNG Human Osteosareoma 
- MNNG (STK) 
FIGURE 5: In Vitro GCV Sensitivity Assay - 
MLM Metastatic Osteosarcoma 
- MLM (STK) 
FIGURE 6: In Vitro GCV Sensitivity Assay - 
TE85 Human Osteosarcoma 
FIGURE 7:  In Vitro GCV Sensitivity Assay - 
MG63 Human Osteosarcoma 
- MG63 (STK) 
FIGURE 8: In Vitro GCV Sensitivity Assay - 
G292 Human Osteosareorna 
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Table 3: Percent Inhibition at 10 yglml GCV 
Cell Line MNNC MLM TEB5 MC63 (3292 
Veebr  
NV 62.0 68.4 46.6 45.9 35.3 
STK 99.5 99.8 99.4 99.7 93.7 
The GCV sensitivity of MNNG was examined more carefully using twelve 
replieales af each cell type incubated with no GCV and in 5 pglrnl GCV. In each case, 
the resuEts are statistically significant at the 95% confidence interval (p < 0.05). The 
MNNG (STK) showed a 99.3% decrease in proiiferation (1569 +/- 254 DPM, versus 
219,321 +/- 28,021 DPM) when incubated in 5 p g / d  GCV as compared to GCV-free 
control MNNG cells. The wild type MNNG line showed a 50.1% inhibition (79,941 +/- 
11,584 DPM versus 160,2633 +/- 31,256 DPM) in 5 pglml GCV. The MNNG (IL2) line 
was also affected by incubation in GGV; a 52.0% decrease (84,856 +/- 16,130 versus 
176,796 +/- 37,647 DPM) was observed in the presence of 5 pg/mI GCV. The 
diflerences between the IL2-tranuducd and wild type MNNG cells are not statistiedly 
significant (p > 0.05). 
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In Vitro Bystander Assay. This tritium incorporation assay was performed on 
each of the five cell lines lo determine the ability of transduced cells to cause the 
concurrent inhibition of unmodified cells. Individual results are described below. 
Coincubation of W N G  (STK) and MNNG (NV) cells resulted in a 
significant inhibition of growth a1 each percent STK tested. An equal mixture of MNNG 
(STK) and MNNG (NV) cells resulted in prolrfemtion which was 99.4% decreased from 
the control of 100% MNNG (NV) cells. With a mixture containing 10% W N G  (STK) 
and 90% MNNG (NV ), a 94.9% decrease in proliferation was seen. At 2% MNNG 
(STK), a 84.25% inhibition was seen. When MNNG (NV) cells were coincubilted with 
both MNNG (STK) and MNNG (IL2) cells, a similar trend is seen, though proliferation is 
decreased less at a given concentration of W C  (NV) cells. For example, at a 502525 
mixture of MNNG (NV), MNNG (STK), and m N G  (IL2) cells, a 98.5% decrease in 
proliferation was seen; at a 90:5:5 ratio, a 93.2% decrease was seen; at a !38 : 1 : t 
mixture, a 52.8% difference was seen compared to the conlroi. No significant trend was 
observed for the coincubation of mixtures of MNNG (NV) and MNWG (IL2) cells; 
proliferation levels remained around 50% of the control or better. fixtures of MNNG 
(STK) and MNNG (IL2) shows that the IL2-trattsducd cells do not constitute a 
significantly different target cell for the bystander factor than do the MNNG (NV) ceHs 
(table 4 and fig 9.) 
Table 4: Percent Inhibition at Varying Ratios of Pretransduced MNNC cells 
Percent Vector- Expected STK : WV STK / EL2 : EL2 : NV STK : IL2 
Positive Cells Inhibition Cells NV Cells Cells CeHs 
100 100 99.4 99.3 38.7 98.7 
50 50 99.4 98.5 51.5 99. l 
25 25 98.6 96.4 41.5 98.2 
10 10 94.9 93 .2  27.7 96.8 
5 5 87.5 87.2 31.8 95.1 
2 2 84.2 52.8 24.8 90.2 
1 1 40.7 2.3 14.4 71.0 
0 0 0 ' 0 0 0 
FIGURE 9: MNNG In Vitro Bystander Assay 
Percent of Vector-Positive Cells 
- MNNG 
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MLM. Coincubation of MLM (STK) and MLM (NV) cells resulted in a 
substantial decrease in proliferation at each ratio tested. An equal mixture of these two 
cell types resulted in a 98.51% inhibition compared to the control of MLM (NV) cells 
alone. With a mixture containing 90% MLM (NV) cells and 10% MLM (STK) cells, an 
89.9% decrease in proliferation was observed. With a mixture containing 2% MLM 
(STK) cells and 98% MLM (NV) celIs, a 76.1% decrease in proliferation was seen. 
When half of the MLM (STK) cells are exchanged for NlLM (IL2) cells, no significant 
increase in inhibition is observed. At a 50:25.25 percent mixture of MLM (NV), MLM 
(STK) and MLM (IL2) cells, a 95.8% inhibition was observed. At a 90 : 5 : 5 mixture, a 
85.8% decrease in proliferation was seen. With 98% MLM (NV) celIs and 1% each of 
the Iransduced cells, a 42.3% decrease in proliferation was observed. There was no 
significant difference between the counts obhined from MLM (NV) cell alone and 
mixtures of MLM (NV) and MLM (IL2) cells. Using MLM (IL2) cells as a target for 
MLM (STK) cells resulted in counts which were not signif'icantiy different from those 
obtained using MLM (NV) cells as a target. See below (table 5 and fig. 10). 
Table 5: Percent Inhibition at Varying Ratios of Pretransduced MLM cells 
Percenl Vector- Expected STK : NV STK / IL2 : IL2 : NV STK : IL2 
Positive Cells Inhibition Cells NV Cells Cells Cells 
1 00 100 98.8 97 3 13.3 98.0 
50 50 98.5 95 8 8.1 98.5 
2 5 25 96.8 94.1 16.6 96.9 
10 10 92.7 92.9 9.7 87.9 
5 5 89.9 85.9 4.1 66.8 
2 2 85.2 61.1 0.4 52.2 
1 1 66.6 42.3 0.8 29.7 
0 0 0 0 0 0 
FIGURE 10: MLM In Vitro Bystander Assay 
Percent of Vector-Positive Cells 
a d  MLM (STK) : (NV) 
--t-- MLM (STWID) : (NV) 
 M N ( 2 )  :(NV) 
- MLM (STK) : (112) 
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. Coincubation of T B 5  (NV) and T H 5  (STK) cells resulted in a decreased 
level of proliferation at each ratio. At an equal mixture of TI335 (NV) and TFB5 (STK) 
cells, the result was a 97.5% inhibition versus TEB5 (NV) cell alone. With a mixture 
containing 90% TEB5 (NV) and 10% TEB5 {STK) cells, a 97.18 decrease was seen. At a 
ralio of 98% TE85 (NV) and 2% TE85 (STK), a 66.9% decrease was observed. 
Exchanging half of the TES5 (STK) cells for TEllS (IL2) cells did no1 significantly 
change the effect. At a 50 : 25 : 25 ratio, a 96.8% decrease in proliferation was seen. At 
a 90 : 20 : 10 ratio, a 93.7% inhibrtion resulted. At 98% TE85 (NV) and one percent of 
each tsansduced cell type, a 72.7% decrease in proliferation was observed. TI335 (1L2) 
was no ditfetent as a target lhan wild type cells, and there was no  significant &Sference in 
the counts obtained at the different mixtures of TEB5 (IL2) and T B 5  (NV) cells. See 
below (table 6 and fig 11). 
Table 6: Percent inhibition a% Varying Ratios of Pretransduced TE85 cells 
Percent Vector- Expected STK : NV STK / TL2 : IL2 : NV STK : IL.2 
Positive Cells Inhibition Cells NV Cells Cells Cells 
100 100 97.6 97.5 6.7 97.3 
50 50 97.4 968 0 97.2 
25 25 97.2 95.6 6.9 96.4 
10 L 0 97.1 94.7 6.1 94.2 
5 5 95.7 87.6 12.4 91.9 
2 2 86.7 72.7 16 0 80.0 
1 1 66.9 a.8 4.2 60.4 
0 0 0 0 18.0 0 
FIGURE 11: TE85 In Vitro Bystander Assay 
Percent of Vector Positive Cells 
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h42c53. Coincubation of MG63 (NV) and MG63 (STK) c e k  resulted in a 
decreased level of proliferation at each ratio. At an equal mixture d M663 (NV) and 
MG63 (STK) cells, the result was a 98.14% inhibition versus MG63 (NV) cell alone. 
With a mixture containing 90% MG63 (IW) and 10% MG63 (STK) cells, a 94.6% 
decrease was seen. At a ratio of 98% MG63 (NV) and 25% M663 (STK), a 77.5% 
decrease was observed. Exchanging half of the MG63 (STK) cells for MC63 (IL2) cells 
did not significantly change the effect, although a lower efficiency of inhibition was seen 
at each ratio. At a 50 : 25 : 25 ratio, a 95.3% decrease in proliferation was seen. At a 90 : 
10 : 10 ratio, a 77.2% decrease in proliferation resulted. At 98% MG63 (NV) and one 
percent of each transduced cell type, a 45.15% inhibition was observed. There was no 
significant difference in the counts obtained at the different mixtures of MG63 (IL2) and 
MG63 (NV) cells, and MG63 (IL2) was not significantly different as a target than wild 
type cells. See below (table 7 and fig. 12). 
Table 7: Percent Inhibition at Varying b t i o s  of Pretransduced MG63 cells 
Percent Vector- Expected STK t NV STK 1 IL2 : I U  : MV STK : 1L2 
Positlve Cells Inhibition Cells NV Cells Cells Cells 
100 1 00 99.1 94.1 9.8 98.3 
50 50 98.1 95.3 2.3 94.2 
25 25 97.8 94.5 9.3 93.8 
10 10 96.3 80.1 15.6 88.0 
5 5 94.7 77.2 33.1 88.7 
2 2 77.5 45.1 18.9 74.8 
1 1 63.5 38.9 6.4 25.6 
0 0 0 0 0 0 
FIGURE 12: MG63 tn Vitro Bystander Assay 
Percent of Vector-Positive Cells 
MG63 (STWILIL) : (NV) 
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G292. Thls cell line showed the lowest response to the bystander effect. 
Moreover, the counts obtained for the first three treatment categories were not 
significantly different between the ratios of 0-958 target cells. Coincubation of G292 
(NV)  cells with 50%- 10%, and 2% (3292 (STK) cells resulted in a decrease ita 
proliferation of 75.32%, 74.148, and 49,35% respectively. Goincubation of G292 (NV) 
cells with 25%. 5%- and 1% each OC G292 (STK) and 6292 (IL2) cells resulted. in a 
decrease in proliferation of 79.8%, 71.88, and 40.1% respectively. Coincubation of 
mixtures of G292 (IL2) cells and G292 (NV) cells resulted in counts which were not 
significantly different from one another, and G292 (IL2) was not significantly different as 
a target than wild type cells. See below (table 8 and fig. 13). 
Table 8: Percent fnhibition at Varying Ratios of Pretransduced 6292 cells 
Percent Vector- Exyccted STK : NV STK / IL2 : IL2 : NV STK : IL2 i% 
Positive Cells Inhibition Cells NV Cells Cells Cells k 
100 100 72.7 81.7 2.0 79.9 F 
50 50 75.3 79.8 11.7 80.1 8 
FIGURE 13: 0292 In Vitro Bystander Assay 
0 6 r  
Percent of Vector Postive Cells 
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MG (TWA A more rigorous assay was deslgned to confirm the trend in tbc 
bystander effect seen in the MNNG line above, using twelve replicates per mixture, with 
mixtures set up as a geometric progression. Two categories of mixtures were made: 
MNNG (STK) and MNNG (NV) cells, and NP1VNG (STK). MNNG (IL2), and MNNG 
(NV) cellg. In the first category, MNNG (STK) and MNNG (NV) cells were plated at the 
following ratios: 1000, 1:W, 298, 4:96, 8:92, 16:84. 32:68, 6436, and 0: 100, at an 
overall concentration of 5x101 cells per ml. Results are shown below (table 9 and fig. 
14). 
Table 9: Absence crf' HS-tk / IL2 Synergy as Shown by 
Percentage Inhibition at Varying Ratios of Wild-Type, 
Tk-Transduced, and 112-Transduced MNNG Cclls. 
The wells having only MNNG (NV) had the highest count (79,940 4- 11,583 
DPM), indicating that the greatest number of cells survived to replicate their DNA in this 
group. Thereafter, an increasing percentage of MNNG (STK) cells resulted in decreased 
DPM, as more cells were subjecled to GCV-mediated inhibition. With 1% MNNG 
(STK), a 46.68 decrease (42,683 +I- 21,766 DPM) in proliferation was seen when 
compared to the MNNG (NV) alone. With 2% MNNG (STK), an 86.2% decrease 
(1 1,058 +I- 1975 DPM) was seen. Wilh 4% MNNG (ST#), a 91.8% decrease in 
proliferation (6585 +/- 1086 DPM) was observed. The mixture of 8% MNNG (STK) 
cells with 92% wild type resulted in a 95.1% inhibition (3918 +1- 630 DPM). With 1 6 8  
MNNG (STK) cells, a 97.3% decrease (21 63 +/- 288 DPM) was seen, With 32% W N G  
(STK) cells, a 98.2% decrease (1450 +/- 159 DPM) was observed. Between each of 
these successive treatment groups, the DPM are significantly different (p < 0.05). 
However, there was no significant difference seen between the 32% and 64% MMNNC 
(ST K) groups. 
To evaluate the synergistic potential d MNNG (IL2), the same ratios of cells as 
above were plated, but using an equal mixture of W N G  (STK) and MNNG (IL2) cells 
Percent Vector-Posi tive Cells 
0 1 2 4 8 16 32 64 100 
STK : NV 
STK/ IL2 : NV 
0 46.6 86.2 91 8 95 1 973 98.2 98.1 98.0 
0 0 7.7 88.0 91.0 94.9 96.9 97.7 98.4 
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where previously lu3NNG (STK) cells had been used singularly. A mixture of 98% wild 
type cells and 1% each MNNG (STK) and MNNG (IL2) resulted in a alight (7.78) 
decrease in proliferation (73,791 +/- 19,371 DPM) from Ihe 100% wild type control. A 
mixture of 96% wild type cella and 2% each MNNG (STK) and MNNC (iL2) resulted in 
a substantial (88%) decrease in proliferation (9574 +/- 1406 DPM). At a 92 : 4 : 4 
mixture, a 91.0% decrease in proliferation (7187 +/- 517 DPM) was observed. Doubling 
the number of lransduced cells to 8% each resulted in a 94.9% decrease in proliferation 
(4080 +/- 5Q1 DPM). A mixture of 16% of each transduced cell type and 68% wild type 
cells resulted in a 96.9% decrease in proliferation (2484 +I- 461 DPM) over the control. 
A mixture of 32% each of MNNG (STK) and MNNG (IL2) along with 368  wild typc 
cells yielded a 97.7% decrease in proliferation (1852 +/- 159 DPM). The values obtained 
from the 2:2:% mixtures through the 32:32:36 mixtures are all significantly diflerent (p < 
0.05) from one another. 
The matter of the HS-tk and IL2 gene products acting synergistically to inhibit 
cellular proliferation, addressed by comparing the results between rows I and 2 in table 9 
above, may be considered from two standpoints: as a constant percentage of tumor cells 
(i.e., comparing a given number in tow 1 with the number directly below in row 2), or as 
a constant percentage of HS-tk-transduced cells (i.e., comparing a given number in row 1 
with the number below and immediately the right in row 2, because, for example, "8% 
transduced cells" in row one and "16% transduced cells "in row 2 each contain 8% STK- 
t r a m d u d  cells.). 1n the first case (when the percentage of tumor cells is held constant), 
the figures are significantly different (p a 0.05) between row 1 and row 2; at a given 
percentage of wild type MNNG cells, an equal mixture of' STK-lransduced and IL2- 
transduced cells results in a relatively lower level of inhibition eompared with STK- 
transduced cells and no IL2-transduced cells. In the second case (when the percentage of 
STK-transduced cells is kept constant between rows 1 and 2), the results obtained from 
comparing between the two rows are not significantly difl'erent, indicating that at a given 
percentage of STK-transduced cells, the level of growth inhibition is unaffected by the 
presence of 112-transduced cells. Thus, a model of synergy between the HS-tk and fL2 
gene products is not supported. 
Figure 14: MNNG In Vitro Bystander Assay 
(Trial 2) 
Percent of Vector-Positive Cells 
- 
u STK : NV 
Preliminary Studies- To test which of' the original four cell lines (MNNG. TE85, 
MG63, and G292) would be lumorigenic in nude mice, two concentrations cells (each in 
0.1 rnl HBSS) were injected bath subcutaneously (3x107 and 2 xl07 cells) and into the 
vascular system through the vcntrol;lteral tail vein ( 2 x 1 0 ~  and 5x10~ cells). Thrce mice 
were injected at each level in each experimental group, for a total oS 24 mice. During tail 
vein injections, a total of four mice &ed (one in a low dose group and ihree in a h g h  dose 
group). Several others experienced whole-body twitching but recovered fully within a 
matter of minutes. All xubcutaneous injections were administered without incident. 
Of the subcutaneous groups, only MNNG was tmmorigenic. No mice receiving 
tail-vein injection of any cell line developed disseminated tumors, though mice receiving 
MNNG intravenously did develop local tumors at the injection site. 
The novel fifth osteosacoma cell line (M.,M) was a metastatic lung tumor from a 
nude mouse receiving an intratibial implant of MNNG cells. This line produced 
subcutaneous growth similar to that of the parental MNNG line, and yielded no 
metastasis when injeckd intravenously. 
Threshold for MNWG tumorigenicity, Varying concentrations of MOPNG cells 
(0.05 ml in HBSS) were injected subcutaneously lo nude mice. No tumors developed in 
ten mice injected with 5x104 cells. In mice injected with 1 xl05 cells, 17 6% (3117) 
developed tumors. Alf mice receiving 2x105 cells or more (N = 380) developed tumors. 
See below (table 10). 
Table 10 : Cellular Threshold for Turnwigenicily of MNNG 
Human Osteosarcoma in Nude Mice 
CELL NUMBER N U M B E R  OF MICE 
DEVELOPlNG TUMORS 
5x104 0 /  10 
1 x 105 3 117 (17.6%) 
2 x 105 20 / 20 
2.5 x 1@ 21 / 21 
5 x  16 8 8 / 8 8  
8 x  I@ 32 / 32 
2 x lo6 1441 I 4 4  
5 x lo6 69 / 69 
1 x 107 3 / 3  
2 x 107 3 / 3  
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Mixture of STK vectar-producer cells and MNNG cells. In an effort to 
determine the relative number of STK vpc needed to completely destroy tumors, twenty 
mice were divided evenly into four groups. Mlce in Group 1 received a subcutaneous 
injection of a mixture of wild type MNNG cells (5x105) and STK vpc (2,5xl0~), a 1:s 
ratio. Mice in Group 2 received a mixture of MNNG (1x10~) and STK vpc (2x106), a 
1 :2 ratio. Mice in Group 3 received a 1 : 1 ratio of each cell type (1x 106 cells each). In 
Group 4, mice received a mixture of MNNG cells ( 1 x 1 0 ~ )  and STK vpc (5x105). a 2.1 
ratio. Beginning on d a y  eight and continuing through day 19, all mice received injections 
of GCV (3 mg in I ml HBSS) twice daily. Measurements of maximal tumor diameter 
were taken daily throughout GCV treatment. 
Control groups consisted of seven mice which received wild type MNNG cells 
(5x105) alone; four were treated with GCV, and the other three were given saline 
injections instead. Also, 12 mice were divided into four groups; thew mice reccived 
identical mixtures of MNNG (NV) and STK vector producer cells as above, but were 
given saline injections instead of GCV. 
Figure 15 shows the results of this experiment (in this and all subsequent graphs, 
arrows depict the range of GCV treatment). Ail mice receiving mixtures of MNNG 
(NV) and STK vpc developed tumors, which began to regress within two to four days 
after the cornmencement of GCV injections. All mice in the experimental groups were 
completely cured, except for one mouse in the group receiving the fewest number of STK 
vpc, which developed regrowth. All mice in control groups experienced progressive 
tumor growth until sacrifice was necessary at day 28. Tumor growth in control mice 
receiving mixtures of MNNG cells and STK vpc and no GCV (not shown) was not. 
significantly different from thaP in mice receiving only MNNG cells and no GCV. There 
was also no significant difference in tumor growth between control mice receiving GCV 
and wntrol mice not receiving GCV. 
FIGURE 15: Mixtures of STK Vpc and MNNG 
(NV) Human Osteosarcoma Cells 
Day of Treatment 
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In Vivo Bystander Assay. (Fig. 16-18). A total of 26 groups were formulated, 
each testing different ratios of MNNG (NV) cells to transduced cells [ m N G  (STK) 
andlor MNNC (1L2)] For clarity" sake, group numbers are followed parenthetically by 
the percentage of transduced cells in the inxulurn From three to I 1  mice were assigned 
to each group, for a total of 144 mice Each mouse received a total of 2x106 cells as a 
subcutaneous injeclion. Except as noted, dl mice developed tumors which increased in 
size from day one to day ten. From day eight to day 19, mlce in groups 1-17 received 
GCV (3 rng in 1 ml HBSS) twice daily. Mice in groups 18-26 did not receive GCV. All 
mice were monitored for up to tea weeks following cumpletioi~ of CSCV therapy. Three 
mice in separate groups (groups 3 (1L2 1001, 10 (STK12.5), and 12 (1L2 12.5)) showed 
regrowth after having been apparently cured; data fmm these animals is not included in 
the graphs showing average tumor volume. Several other groups (generally 1162 groups 
without GCV) contained multiple mice showing regrowth; measurements from these 
mice were included graphically. Five mice died from GCV toxicity (defined below) 
during the course of injections; these mice are included in the averaged data. All healthy 
mice were followed for a minimum of six weeks prior to termination of the experiment. 
S b n d  NV Figure 16 below shows graphically the results from all 
groups receiving MNNG (STK) cells, including controls. Table 11 below shows the 
percentage of mice cured in each group. 
Table t 1: in  vivo Bystander Experiment: STK Groups 
-- - 
GROUP Number of Percent 
Mce Cured 
GR 1 (STK 100) 5 / 5  100 
GR 4 (STK 50) 10 i 10 100 
GR 7 (STK 25) 11 111 1 00 
GR 10 (STK 12.5) 10 / I I 91 
GR 13 (STK 5) 3 / 3  100 
GR 17 (STK 0) 015 0 
FIGURE 16: In Vlvo Bystander Experiment: 
All STK Groups 
Day of Treatment 
.8 Gr 1 : STK(100) 
- Gr 4: STKNV (50:50) 
 Gr 7 STK:NV (25:75) 
- Gr 10: STK:NV (f  2.5:87.5) 
 GR13:STK:NV(5:95) 
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Group 1 (STK100) contained five mice, each of whicb developed tumors and 
were cured by day 28. Group 4 (STKSO) contained ten mice, all of which developed 
tumors that were cured by day 28. Group 7 (STK25) contained 11 mice, all of which 
developed tumors that were cured by day 23 .  Group 10 (STK12.5) had 1 1 mice; ten of 
these mice (91%) were cured by clay 28. The other mouse had no palpable tumor from 
days 22 to 36, then experienced regrowth (8 mm3 by day 43 up to a terminal volume of 
360 mm3). Group 13 (STK 5) contained three mice. all of which developed tumors that 
were cured by day 25. 
Group 17 (STK 0) was a control group containing fivc rmce which received only 
MNNG (NV) cells; all of these mice received the standard GCV cycle, and showed 
progressive growth (to a final average of 580 mm3) until euthanasia was necessary at day 
28. Two other control groups not receiving GCV werc present in the STK-containing 
collection. Group 20 (STKSO) contained three mice, each of which showed progressive 
growth (to a final average of 595 mm3) and was sacrificed on day 39. Group 2 1 (STK25) 
also contained three mice, each of which show& progressive growth (to a final average 
of 460 mm3) until euthanasia at day 46. 
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L W N V  Figure 17 depicts the results obtained from the ten groups 
receiving mixtures of W N G  (1L2) cells and MNNG (NV) cells; table 12 below shows 
the percentage of cured mice by group. 
Table 12: In vivo Bystander Experiment.: IL2 Groups 
GROUP Number 01 Percent 
Mice Cured 
GM 3 (ILZ 100) 4 1 5  80 
No GCV 
No GCV 
GR 22 (IL2 50), No GCV 2 1 3 67 
GR 23 ( I U  25), No GCV 2 13 67 
GR 24 (IL2 lo), No GCV 1 / 4 25 
Groups 3, 6, 9, 12. 15, and 17 each contained five mice, all of which recelved 
CCV; mice in groups 18, 19,22, 23, and 24 did no1 receive GCV. M c e  in Group 3 (1L2 
100) received subcutaneous injections of only MNNG (1L2) cells m d  GCV. Each mouse 
showed small tumor growth (to an average maximal volume of 3 56 mm3 by day ten). 
Four of these mice (80%) were cured completely by day 24. The fifth mouse appeared to 
be turnor-he, then shawed small but steady regrowth (3 m d )  from days 64-78. Mice in 
Group 6 (1L2 50) all showed small tumor growth (average maximal volume of 3.14 mm3 
at day ten), followed by total ablation by day 20. Mice in Group 9 (1L2 25) each 
developed a small tumor (maximum average volume of 6.07 mm3 by day 10) which was 
eliminated compietely by day 20. a c e  in Group 12 (IL2 12.5) each initially developad a 
small tumor (average maxim1 volume of 4-92 at day 13); tumors on four of these rnice 
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(80%) d i s a p p e d  permanently by day 28. The other mouse showed an 80% regression 
in tumor volume, but the tumor then expanded progressively From day 37-64, to a final 
volume of 377 mm3. Mice in Group 15 (IL2 5) each developed tumors; by day 18, the 
average tumor volume was 60.32 mm3. Thereafter, one mouse (201) was cured 
cornplelely by day 46 and showed no regrowth. The other four mice showed a 54% 
average regression (p < 0.05) in tumor mass, followed by progressive growth to an 
average maximal volume of 536 mm3 by day 53. Two of these mice showed no visible 
tumor from days 28 - 35, but then deveiopd regrowth. 
The remaining IL2 groups did not receive GCV. Group 18 (IL2 100) contained 
three mice, each which received an implant of 2x106 MNNG (IL2) cells. Only one of 
these mice showed any tumor growth whatsoever, and this disappeared by day ten. 
Gmup 19 (IL2 100) contained three mice, each of which received 5x106 MNNG (1L2) 
cells. Each of these mice developed a small h~mor (average maximal vdume of 3.66 
mm3 by day 8), which was eliminated by day 18. The fallowing three groups received 
mixtures of MNNG (IL2) and G (NV) cells and no CCV. Group 22 (IL2 50) 
contained three mice, each of which developed small tumors (maximum average volume 
of 4.19 mm3 at day 8) that dissipated by day 25. Two mice (67%) proved to be cured 
permanently. The third developed small but persistent regrowth (2 mm3 by day 53). 
Group 23 (IL2 25) contained 3 mice, each of which showed small tumor growth (average 
maximal volume of 4.36 mm3 by day 8) then complete regression. Two mice (67%) 
were cured permanently. The other mouse developed substantial regrowth (100 mm3 by 
day 53). Croup 24 (IL2 10) contained 4 mice. One mouse (25%) was cured completely 
by day 28. The other three showed some regression then progressive growth (average 
terminal volume of 27 mm3 on day 57). 
FIGURE 17: In Vivo Bystander Experiment: 
All IL-2 Groups 
Day of Treatment 
- Gr 9:lU:NV (25~75) 
 Gr12:IW:NV(12.5:87.5) 
- Grf 5:lU:NV (5:95) 
 Gr17:NV(100) 
- GR18:2M IF2(100), NoGCV 
 GR19:5M IL2(100), NoGCV 
- GR22:1E:NV(50:50) ,NoGCV 
 GFt23:112:NV(25:75),NoGCV 
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S NV mirsluca In these groups, MNNG (STK) and MNNG (ILZ) 
cells were introduced in equal proportions along with varying levels of MNNG (NV) 
cells. The total number of transduced cells is designed in the notations that follow. 
Figure 18 shows the rcsuIts obtained from thc eight groups that received mixtures of all 
three cell types. Table 13 below shows the number of cured mice by group. 
Table 13: In vivo Bystander Assay: STK 1 1L2 Groups 
GROUP Number of Pcrcent 
M c e  Cured 
GR 2 (STWIL2 100) 5 / 5  100 
GR 5 (STK / 1L2 50) 10 1 10 100 
GR 8 (STK 1 IL2 25) 11 111 100 
GR 11 (STK I IL2 12.5) 11 / 11 100 
GR 14 (STWIL2 5) 4 1 4  100 
GR 16 (STWIL2 1) 2 / 5  40 
GR 17 (STWIL2 0) 0 I 5  0 
GR 25 (STNIL2 25), 213 67 
No GCV 
GR 26 (STK/IL2 12.5), 113 3 3 
No GCV 
FIGURE 18: In Vivo Bystander Experiment 
All STK-112 Groups 
Day of Treatment 
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Group 2 (STWIL2 100) contained five mice, all of whzch developed small tumors 
(average ma.limal volume of 5.97 mm3 on day eight), that were eliminated by day 20. 
Group 5 W'K/IL:! 50) had ten rnrce, all of which showed moderate growth (peaking at an 
average volume of 9.48 mm3 on day 8), followed by complete regression. One mouse 
died of GCV toxicity on day 22. Group 8 (STK/IL2 25) contained 11 mice. each of 
which showed moderate tumor growth (a maximal average volume of 5.61 mm3 on day 
10)- then complete regression by day 20. Group 1 1 (STWIL2 12.5) had 1 1 mice, each of 
showed small tumor growth, peaking on day ten with a average volume of 6.38 m d .  By 
day 24, all mice had been completely cured. Group 14 (STWIL2 5) contained four mice, 
each of which showed moderate growth, to a maximal average of 20.5 mm3 by day 13. 
Each tumor had disappeared by day 20. One mouse in this group d i d  of GCV toxicity. 
Group 16 (STK/LL2 1) had 5 mice, all of which developed tumors of moderate size, 
which peaked on day 13 at an average volume of 44.7 mm3. Two mice died on day 25 
due to GCV toxicily. On the other three mice, no visibie tumor rernalned by day 28; one 
mouse showed small regrowth beginning on day 45. The other ~ w o  (40%) were cured 
permanently. 
Two control groups received a combination of all three cell types but ao  GCV. 
Each of the three mice in Group 25 (STKlIL2 50); by day 18, the tumors had grown to an 
average volume of 40.67 mm3, but then began to shrink. By day 32, two mice (67%) had 
been cured and showed no regrowth. The other mouse showed a 34.6% regression in 
tumor size by day 28, but then steady regrowth (to 26.2 mm3 by day 53). Group 26 
(STWIL2 25) contained three mice. One of these mice (33%) was cured by day 25. The 
other two showed slight (258) regression, then progressive regrowth (to an average of 
189 9 mm3 by day 53). 
Double Tumor Experiment. (Fig 19-23). Forty-two nudc mice wcre divided 
into four groups. On day one, each mouse received a subcutaneous injection of MNNG 
(NV) cells ( 1 x 1 0 ~ )  on the right ventral side. By day six, all mice had developed dense. 
nodular tumors (average volume 26.19 +/- 3.12 mm3). At this time, sccsndary tumors 
(2x107 cells per implant) were induced with MNNG cells which had been transduced 
with the STK, IL2 or BAG gene, These tumor cells were injected subcutaneously on the 
left ventral side at a distance ol' approximately one centimeter from the nearest border of 
tbe ftrst tumor. Control mice (the same as those in the bystander experiment) received a 
similar implant of lWlJNG (NV) cells, no secondary tumor, and 12 days of GCV. Table 
14 below shows thc number of animdls showing a significant responsc (i.e., at least a 
50% reduction in the volume ol' the primary MNNG (NV) tumor) in each group. Figure 
19 shows the composite results graphically. 
Table 14: Double Tumor Experiment 
GROUP: Number of Percent Percent 
Responders Responders Cured 
GR 1 (STK) 10 / 12 83 0 
GR 2 (STK 1 IL2) 13 / 18 72 11 
GR 3 (IL2) 3 1 6  50 0 
GR 4 (BAG) 616 0 0 
FIGURE 19: Double Tumor Experiment 
GR1, NV tumor 
GR1, STK tumor 
GR2, NV tumor 
GR2, STW112 tumor 
GR3, NV tumor 
GR3.112 tumor 
GR4, NV tumor 
GR4, BAG tumor 
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Group One contained twelve mice, each of which receivcd MNNG (STK) cells 
( 2x10~  each) on day 6. By day 13, the first tumors had expanded considerably, Lo an 
average volume of 219.8 +/- 62.3 mm3. GCV injections were administered twice daily 
from day 14-25. Ten mice (83%) showed a partial response, experiencing at least a 60% 
reduction in the primary tumor volume. In thcse mice, the average reduction was 80.7% 
(688.5 +I- 260 9 mm3 to 136.6 +/- 84 2 mm3). occurring on average from day 18.2 to 
25.3. Thereafter, each mouse showed considerable regrowth, to an average volume of 
484.4 +/- 353.1 mm3 (a 356% increase lrorn the avenge low volume) by day 41 when 
the experimenl was terminated for this group. Two mice were unresponsive and showed 
progresswe growth of the primary tumor. Two toxicity deaths were seen in this group 
near thc end of GCV treatment. 
The secondary WIPJNG(STK) tumors in Group 1 grew to an average maximal 
volume of 112.2 4-1- 59.5 mm3 by day 16 (i.e., three days into GCV treatment). 
Thereafter, lhese lumors shrank quickly. Of the ten mice living by the termination date, 
sevcn showed no rernalning secondary tumors; the other three ha3 an average tumor 
volume of 12.83 i t -  11.83 mm3. See below (fig. 20). 
FIGURE 20: Double Tumor Experiment - Group 1 
MNNG (STK) Secondary Tumor 
Day of Treatment 
- GRI , STK tumor 
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Croup 2 contained 18 mice, each received a secondary implant of MNNG(STK) 
and MNNG(IL2) cells (1x10~ each) on day six. By day 13. the initial tumors had 
increased greatly in voIurnc to an average of 247.1 +I- 59.9 mm3. GCV was 
administered from day 14-25. Thirteen micc (72%) showcd at leas1 a partial response to 
therapy, experiencing a 50% or greater reduction in volume of the primary tumor; two of 
these mice (1 1%) were cured completely. The 11 partial responders showed an average 
regression of 82.246 (from 820 77 +/- 307.13 mrn3 to 146 44 +I- 56.02 rnrn3), occurring 
on average from day 20.8 to day 26.2. Each of these mice showed regrowth (to a 
maximal average of 806 19 +I- 275.7 mm3) by the completion of the experiment. 
Tumors on Lhe two cured mice went from maximal volumes of 395.8 mm3 (day 16) and 
150.8 mm3 (day 19) to zero mm3 by day 41 and 49 Each mouse was monitored For at 
least 60 days after the tumor was gone. Five mice (28%) in Group 2 did not show a1 least 
a 50% regression in tumor volume; three of these showed no regression whatsoever. 
Ovcrall, two mice in this group died near the end of GCV treatment. The gecondary 
tumors in Group Two grew to a maximal average volume of 32.41 +I- 1 1.8 mm3 by day 
16. Each of these tumors had been eradicated by day 41, 12 of 16 (75%) had disappc~ed 
by day 34. See below (fig. 21). 
FIGURE 21: Double Tumor Experiment - Group 2 
MNNG (STK)/MNNG (112) Secondary Tumor 
Day of Treatment 
- GR2 (NV): cured 
 GR2 (NV): nonresponders 
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Group Three contained six mice. each of which received a secondary implant of 
MNNC cells. By day 13. the first tumors had grown to an average volume of 266.7 
+I- 102.5 mm3. GCV treatment was administered from day 14-25. Three mice (50%) 
showed a partial response to therapy. Oize mouse showed a 89.7% decrease in tumor 
volume (1590 mm3 on day 28 to 163.4 mm3 on day 41). The two other mice showed 
even greater response levels: 98.5% reduction (1246 mm3 to 18.9 mm3) and 99.8% 
reduction (678.6 mm3 to 1.05 m3), each between days 2 1 and 49. However, all three 
of these mice developed massive regrowth (to an average of 867 mm3) by the end d the 
experiment, The other three mice did not show a significant decrease in the volume of 
the first tumor; one mouse died near the end of GCV treatment and had faaled to show 
any evidence of regression. The secondary tumors in Group Three grew to m average 
maximal volume of 40.6 +I- 22.6 mm3 between days 16 and 19, and had all vanished by 
day 49 in surviving mice. See below (fig. 22) 
Croup 4 contained six mice, each of which rcccived a secondary implant of 
MNNG (BAG) cells. By day 13, the first tumors had grown lo an average volume of 
224.7 +/- 137 6 mm3 All of these mice received the standard regimen of GCV therapy. 
Each primary tumor grew progressively to a maximal volume of 776.1 +/- 720.5 mm3. 
The W N G  (BAG) tumors also grew progressively, to a maximal volume of 420.3 +/- 
234.9 mm3. All mice survived until day 28, when euthanasia was necessary. At lhis 
time, primary tumors were harvested, grown in culture, and stained with X-Gal; all 
tumors stained negatively, See below (fig. 23). 
FIGLIRE 22: Double Tumor Experiment - Group 3 
MNNG (IL2) Secondary Tumor 
Day of Treatment 
a GR3: NV turnot: partial respndrs 
----t-- GR3: NV tumoc nonresponders 
 GR3: 112 tumor 
FIGURE 23: Double Tumor Experiment - Group 4 
MNNG (BAG) Secondary Tumor 
Day of Treatment 
I Y GR4, NV tumor 1- GR4, BAG tumor I 
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In Vivo Transduction EPficiency. Five subcutaneous MNNG tumors were 
injected with BAG vpc (described below under Treatment of Established Subcutaneous 
Osteosarcomas, Trial Two). Twenty-six days later, the mice were sacrificed and the 
tumors were harvested and grown in culture for two weeks. The perantage of wild type 
cells which were successfully transduced via retroviral vectors with the BAG gene was 
determined by staining harvested tumor cells with X-Gal. The results of X-Gal staining 
of these five tumors were variable. One t m o r  showed only 0.94% positively stained 
cells. In another tumor, the BAG gene was transferred more efficiently, at 17.088. The 
average percentage of positive cells from these tumors w-as 6.64%. See table 15 below. 
Control tumors, injected with STK vpe, were completely negative in that X-Gal staining 
resulted in no color change of the cells (data not shown). 
Table 15 In vivo Transduction Efficiency of the BAG Gene 
Number of Percent 
Positive Cells 
Tumor 1 45 / 564 7.98 
Tumor 2 47 / 936 5.02 
Tumor 3 174 / 1193 14.59 
Tumor 4 8 / 861 0.93 
Tumor 5 12 / 986 1.22 
AVERAGE 5.95 
Treatment of Established Sukutaneaus Osteosarcomas. (Fig. 24-30). Three 
separate trials were made lo treat existing subcutaneous MNNG (NV) tulnors by the 
injection of vector-producer cells. The results from each experiment are described below. 
3haLQw. Sixty-six nude mice were divided into four groups. On day one. 
MNNG cells (5x10~) were intmduced nubcutaneously to the mid ventral surface. By day 
five, dense, nodular tumors had formed on all mice, with a maximal diameter of 5.73 +1- 
0.20 mm. On day five, all mice received an injection of vpc (1.5 x lo7) directly into the 
growing tumor mass. The 17 mice in Group 1 received STK vpc; the seventeen mice in 
Group 2 rece~ved IL2 vpc; the 16 mice in Croup 3 received a mixture of STK and IL2 
vpc ( 7 . 5 ~ 1 0 ~  cells each, fig. 26); and the 16 mice in Group 4 received BAG vpc (fig. 27). 
At least haif the mice in each group received GCV (3 mg in 1 ml HBSS) twice daily 
between days 13 and 24; the other mice received saline injections. The composik results 
are shown below (fig. 24). The number of responding mice (i.e.. those experiencing at 
least a 50% reduction in tumor volume) in GCV-receiving groups are described in table 
16 below. 
Table 16: Treatment of Established MNNG Tumors with Vpc (Trial 1) 
-- - 
GROUP Number of Percenl Cured 
esponders 
GR 1 (STK vpc) 4 / 10 40 0 
GR 2 (IL2 vpc) 3 / 9  33 
GR 3 (STK and 1 1 10 10 1 (10%) 
CR 4 (BAG vgc) 0 ( 8 0 0 
FIGURE 24: Treatment of Established 
Osteosarcomas with Vpc (Trial I) 
Y GR 1 A: STK nonresponders (N=6) 
GR 1 partial responders (N=4) 
GR lB: No GCV (N=7) 
GR 214: 112 nonresponders (N=6) 
GR 2partial responders (N=3) 
GR 28: NO GCV (N=8) 
GR 3A: STW112 nonresp. (N=9) 
GR 3 cured (N=l) 
GR 3B: NO GCV (N=6) 
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Four of ten mice (40%) in Group 1 (STK vpc) rccciving GCV showed a partial 
response to therapy, expcricncing at least a 50% reduction In maximal [urnor diameter. 
By the first day of' GCV inject~ons (day 13), the maximal tumor dlameter in among thesc 
mice was 14.75 +I- 2.0 mrn. By the next day, the maximal d~ameter had increased to 
15.75 +/- 2.0 mm; Midway through the GCV course (day 18). the tumors had not 
changed signiCicantly in size (maximal diameter of 15.5 +/- 5.6 mm). Thereafter, the 
tumors began a gradual shrinkage process. By the final day of GCV treatmen1 (day 241, 
the maximal tumor diameter had shrunk Lo 10.33 +I- 3.67 mm. The tumor diameters 
reached an average low at day 29, at 7.67 mm +/- 1.83 mm, or a reduction of 51.3% from 
the  largest diameter. After this, the tumors began to expand oncc again, to a maximal 
dimeter of 21.0 +/- 2.25 mm at day 50, when the mice were euthanizd. 
Six of the ten mice (60%) receiving GCV ia Group 1 (STK vpc) did not show a 
significant response to therapy. At day 13, the average maximal tumor diameter was 12.5 
+/- 2.46 mm. Midway through the CCV treatment course (day 18), the tumors had 
increased in dimeter to an average of 14.17 t / -  4.11 mm. By day 24, the average 
maximal tumor diameter of these mice had grown to 15 +/- 5.49 mm, and the mice were 
euthanized. One of these mice had died of GCV toxicity on 18. 
Seven mice in Group I (STK vpc) received saline injeclions rather than GCV; 
these mice showed progressive tumor growth (day 13: maximal diameter = 16.57 +/- 
1.29 mm; day 18: 1 8.71 +/- 1.98 mm; day 24: 24.73 +/- 4.97 mm) until euthanasia was 
necessary at day 24. The average tumor measurements for these mice were significantly 
larger (up to 39.370) at corresponding days than those for the aonresponders in Group 1 
who rece~ved GCV. See below (fig. 25). 
FIGURE 25: Treatment of Established Osteosarcomas 
with SrK Vpc (Trlal 1) 
Day of Treatment 
--t-- GR 1 partial responders (N4)  
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In Group 2 (JL2 vp), nine mice received CleV and eight received saline. Three 
of h e  mice (33%) in the treatment group showed a significant reduction (an average of 
77.8%) in tumor diameter. By day 13, these three micc kad a maxirnal tumor diameter of 
12.33 +/- 1.43 mm; midway through GCV treatment (day 18). the tumor diameters had 
increased slightly, at 13.33 +/- 4.4 rnm. By Ehe final day of GCV injections (day M), the 
average maximal diameter had decreased significantly to 8.33 +/- 2.52 mm. The 
shrinkage trend continued until day 29, when the smallest maximal diametcr (3.33 +I-  
3.21 mm) was achieved. Thereafter, the tumors began to grow again, to a maximal 
diameter of 12.0 +/- 4.58 mm by day 39, when the mice were euthanized. 
SIX of the Croup 2 mice receiving CCV (67%) showed no significant reduction in 
tumor sim throughout the experiment. On day 13, the average maximal tumor diameter 
was 13.33 +/- 1.7 mm; these had expanded to 15.83 +/- 2.14 mm by day 18, and remained 
near t h s  s i x  until day 24 (15.178 +/- 3.9 mm) until these mice were euthanized. The 
eight mice in Group 2 which did not receive GCV showed progressive tumor growth 
which was not significantly different than the namespunding mice who did receive CCV. 
On day 13, these control mice had an average tumor measurement of 13.88 +/- 1.13 mm; 
by day 18, these rumors had grown to 15.75 4/- 1.07 mm, and by day 24, growth had 
coatinued to an average rna~imal diameter of 20.63 +/- 3.623 mm. See below (fig. 26). 
FIGURE 26: Treatment of Established 
Osteosarcomas with IL2 Vpc 
Day of Treatment 
GR2A: Partial responders (N=3) 
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In Group 3, mice received a mixture of STK and 1L2 vpc. Nine ol' the ten mice 
(W%) in the GCV-positive subgroup showed nu significant reduction in tumor size. By 
the first day of GCV treatment, the maximal tumor diameter was 10.89 +/- 3.1 mm; by 
day 18, the average diameter had increased to 15.89 +/- 2.05 mm; and by day 24, the 
average diameter had increased to 16.33 +I-  3.8 mm, and the mice were euthanized. One 
mouse (10%) in this group was c u r d  its tumor as a result of therapy. At day 11, the 
maximal diameter of this tumor was 7 mm, by day 17, no evidence of tumor remained. 
This mouse showed transient regrowth (2 mm) between days 24  and 26, but then 
remained tumor-free throughout the eight-week follow-up period. The six mice in Group 
3 who received no GCV showed progressive tumor growth; on day 13, the average 
maximal tumor diameter of these mice was 14.0 +/- 1.32 mm. By day 18, the diameter 
had increawd to 19.0 +/- 2.2 mm, and by day M, the diameter peaked at 25.33 +/- 5.37 
mm, at which point the animals were sacrificed. There was no significant difference in 
the growth patterns of the nonresponding GCV-positive mice and the control mice not 
receiving GCV. See below (fig 27). 
In Group 4, mice received BAG vpe. The eight mice in this group who received 
CCV showed a slight (20.7%) shrinkage of maximal tumor volume. On day 13, the 
average tumor was 15.13 +/- 0.94 rnm in diameter. Midway through the GCV course 
(day 18). the tumors were not significantly different in size. at 14.38 +/- 2.44. mm; it was 
on this day that the difference in tumor size between these mice and the controls not 
receiving GCV became statistically significant (p -c 0.05). By the last day of CCV, the 
tumors averaged 12.238 +/- 4.46 mm in diameter. For the control mice, progressive 
growth was obsewcd (14.63 +/- 2.32 rnm al day 13; 18.88 +/- 1.63 mm at day 18; 26.43 
+/- 3.2 rnm at day 24). See below (fig. 28). 
FIGURE 27: Treatment of Established Osteosarcomas 
with STK and 112 VPCs (Trial 1) 
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FIGURE 28: Treatment ot Established Osteosarcornas 
with BAG Vpc (Trlal 1) 
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. In this trial, thirty nude mice were divided into two groups. An 
initial inoculum of MNNG (NV) celts ( 5 ~ ~ 5 )  w s  given to each of the thirty nude mice. 
By day 5,  these tumors had grown to an average volume of' 61.4 +/- 14.5 cubic mm. At 
this time, vector producer cetls were ~ajected intraturnoratly. Group $A contained ten 
mice, which received a single dose of STK vpc (2x107). Group 1B contained ten mice 
which received one dose of STK vpc (2x107) and would receive a second dose of STK 
vpc two weeks later'. Group 2A contained five mice which received a single dose of 
BAG vpc (2x10~) Group 28 contained five mice wttich received one dose of BAG vpc 
and would receive a second dose of BAG vpc two weeks later. Table 17 below shows the 
number of mice per group showing at least a partial rcsponse (i.e,, a 50% or greater 
reduction in tumor volume) to therapy. The overall results are depicted graphically bebw 
(fig. 29). 
Table 17: Treatment of Established MNNG Tumors with Vpc (Trial 2)  
- - 
GROUP Number of Percent Cured 
Responders 
GR 1A (Single STK 9 / 13 69 1 (8%) 
vpc injection) 
GR 1B (Two STK 6 /  6 100 0 
vpc injections) 
GR 2 (Single BAG 0 1 9 0 0 
FIGURE 29: Treatment of Established Osteosarcornas 
with Wpc (Trial 2) 
GR1 C (STK): Cured 
Day of Treatment 
KEY 
GRIA = partial responders (N=0) 
GRIB = two STK vpc treatments (N=6) 
GR1 C = cored mouse (N=l) 
GR1 D = nor~responders (N=4) 
GR2 = controls (N=9) 
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Each of the twenty mice in Gmup 1 received STK vpc (2x107 cells). By day 13. 
these tumors had grown to an average volume of 171.6 +/- 23 cubic mm. GCV 
commenced a1 day 13. and continued for twelve days for those mice in Croup 1A and one 
week for those in Group 18. After a recovery period, mice in Group 1B received a 
second intratumorai injection of STK vpc on day 46. followed by a twelve day course of 
GCV from days 53-59. In Group 1 A, two mice died from GCV toxicity. In Group 13, 
eight mice were given a second STK vpc injection; six of these mice survived the 
process. The two other mice in Group SB had highly vascular tumors and were excluded 
from a second vpc injection; they were regrouped into Group 1A and given GCV for an 
additional five days to complete the twelve day course. Surviving mice were followed 
until day 85. 
One mouse in Group 1A was cured of its tumor. The tumor volume of this mouse 
peaked on day 15 (the third day of GCV) at 272.3 cubic mm; it remained this size until 
near the end of the GCV period. On day 22, the tumor had shrunk 23% to  a volume of 
209.44 cubic mm. Two days later, it had decreased in voluine by another 72%. to 58.6 
cubic mm. By day 39, just a residual inflammation remained, and n o  lraces of any tumor 
remained by day 49. This mouse remained tumor-free for the next six week9 
Eight mice of 13 in Group 1A (STK x l )  showed a partiai response to treatment. 
The average tumor volume of these mice peaked on day 15 at 221.0 +/- 50.6 cubic mm. 
During the course of GCV treatment, these tumors shrank progressively, to 183.9 +/- 75 
cubic rnm (16.8%) by day 18, to an average low of 35.9 +I- 22.4 cubic mm (an average 
bta2 rcduclion of 83.8%) after the completion of GCV at day 26. Each d these mice then 
showed substantid regrowth until euthanasia was necessary. 
Four mjce in Group 1A (STK x l )  showed no sign~t'icant response. From an 
average volume of 198.4 +I- 63 cubic mm at day 13, the tumors nearly doubled in size $0 
369.1 +/- 62.9 cubic mrn by day 22 at the end of GCV treatment. These animals were 
euthanized at day 26. 
k h  of the six mice in Group 1B (STK x2) showed a significant (p< 0.05) initial 
response to treatmeat. By day 13 (when primary GCV treatment was initiated), these 
mice had tumors with an average volume of 145.6 +I- 55.8 cubic mm. The tumors 
peaked in size on day 15, with an average volume of 177.3 +/- 67.6 cubic mm. 
Thereafter, the tumors began to decline in size; by day 20 (the final day in the initial 
GCV pcriad) the tumors had shrunk by 25.9% Lu an averagc volume of 131.3 +/- 92 mm. 
This trend cont~nued until day 31, when the tumors were at an average low with a volume 
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of' 113.4 +I- 64.4 cubic mm. Three of the su mice began to experience regrowth at ( ~ s  
point; the other three continued to show regression, 10 avcrage of 13.N +/- 4.0 cubic 
mm at day 39; thereafter, these mice too began to show regrowth of the tumor. At day 
46, a ~ ~ o n d  STK vPc injection (1.5~10' cells) was given intraturnoraily. The tumors 
were highly variable in size at this point (10.47, 31.42, 36.65, 188.5, 263.9, and 769.7 
cubic m). BY day 53, the tum~rs  had grown by an average of 19.8% to 270.3 +/- 236 
cubic mm; at this point. GCV was again commenced for a week By day 56, each of the 
six tumors had begun to regress again, to an average of 155.5 +/- 143 mm, which was 
425% smaller than three days earlier. Two of the six mice became sick and died on daya 
57 and 59. The four other mice continued to show regression. By day 61, the tumor 
volume average was 96.08 +I- 127 cubic mm, or f54.495 less than the previous high for 
these four mice. By day 68, these four tumors were at an averagc low volume of 79.3 +/- 
78.6 cubic mm. After this, the tumors again began to grow, until it became necessary to 
euthanize the animals. 
Group 2 contained ten mice, each of which received an injection of BAG vpc 
(2x107 cells) directly into the tumor on day 5. By day 13, the tumors had increased in 
size to an average volume of 152.2 +/- 40.5 cubic mm. Mice in Group 2A were given the 
standard 12-day GCV course, while those in Group 2B received GCV for one week only. 
In Group 2A, ow mouse died midway through the CCV injection cycle. In Group 2B, 
three of three mice died after receiving a second BAG injection on day 31. At this time, 
the remaining five mice in Group 2 were euthanized and the tumors werc harvested, 
cultured, a d  stained with X-Gal to measure the efficiency of gene transfer. See table 15 
above. 
. 
Twenty-one nude mice were given a subcutaneous inoculum of 
MNNG (NV) cells ( 2 . 5 ~ 1 6 )  on day 1. By day seven, all mice had developed tumors 
with an average volume of 2.13 +/- 0.70 m. At this time, STK vector producer cells 
(1 5x107) were injected as a single inoeulum into the tumor mass. GCV was 
&dminiSkred from day 13 to day 24. Two mice (9.5%) died from apparent GCV toxicity 
during the treatment course. The results of this experiment are summarized in  able 18 
&]ow, and depicted graphically in Figure 30. 
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Table 18: Treatment of Establishd MNNG Tumors with STK Vpc (Trial 3) 
Number of Perccl~t Cured 
Responders 
Three of the ninctecn informative mce  (15.8%) were cured of their tumors as a 
result of the genetic therapy. Two of these mice had tumors which remained relalively 
small (maximal volume of 15.71 cubic mm and 33.0 cubic mrn on days 13 and 14 
respectively), the other mouse developed a larger tumor, which peaked in size at 251.3 
cubic mm on day 16. By the last day of GCV treatment, each mouse had only residual 
tumors (average volume 4.89 +/- 3.7 cubic mm). By day 41, the sltes which had been 
tumorous were completely normal in appearance. These rraiee remained tumor-free over 
the next three weeks. 
Six (31.6%) mice showed a partial response to therapy, experiencing at least a 
70% reduction (average = 83%) in tumor volume. Two of these miee (10.5%) showed 
ovcr a 908 reduction ia tumor volume. On day ten, tumors of these mice had an average 
volume of 33.5 +/- 7.7 cubic mrn. By the beginning of the first day of GCV trealmenl, 
the average volume had nearly quadrupled to 121 +/- 45.6 cubic mm. The average tumor 
volume peaked at day 15, on the third day of GCV treatment, at 215.5 +/- 78.7 cubic m. 
Thereaftcr, the tumors began Lo shrink. On the final day of' CCV treatment, the tumors 
had shrunk to 133.4 +/- 106.6 cubic mrn, an average of 35% from the maximal average 
volume. The average minimal volume in this group was seen on day 28, when turnors 
had a volume of 60.3 +/- 26.1 cubic mm. Therealter, the tumor volumcs began to climb 
steadily, to a level above the pre-lreatment high (average = 3 12.3 +/- 144.4 cubic mm) by 
day 48. 
Ten mice (52.6%) showed no significant reduction in tumor volume throughout 
the treatment course. On day tea, the miee in this group had tumors which averaged 15.1 
+/- 5 cubic mm in volume. By day 13, the tumors had more than quadrupled in size, to 
an average volume of 65.6 +/- 29 cubic m. Between days 14 and 16, the tumors grew 
progressively but at a slower rate, to an average of 103.2 +/- 34.7 cubic mm. Thereafter, 
the tumors grew rapidly, to an average volume of 172.3 +/- 29.5 mrn on day 24, to a 
maximum of 296.9 +/- 57.3 cubic mm, when the rmce were euthanizcd. See below (fig. 
30). 
FIGURE 30: Treatment of Established Osteosarcornas 
with STK Vpc (Trial 3) 
Day of Treatment 
DISCUSSION 
Cells 
Four human osteosarcoma cell lines were obtained from American Type Culture 
Collection. The TE85 line originated in 1975 from an osteomcoma of a 13-year old 
female patient. 153 This line was subsequently transformed in v i m  by N-methyl-N'-nitro- 
N-nitrosoguanidine (0.01 pglml) to  form the highly malignant MNNG cell line. 154 The 
c-met oncogene is reportedly activated in MNNG cells.155 The MG63 tine was originally 
derived in 1977 from an osteosarcoma of a 14-year old male; this cell line is nobworthy 
in that it is reported to produce high levels of fibroblastic interferon.156 The G292 cell 
line originated from an osteosarcoma of a Pyear old female in 1976.157 
The MLM line was a lung metastasis derived from an orthotopic implanl of 
MNNG cells into the tibid tuberosity of a nude mouse in 1993 at the Human Gene 
Therapy Research Institute. Because the spontaneous development of Iung tumors in 
nude mice is a very rare event.158 it is a safe assessment that the Iung tumor arose from 
MNNG cells which traveled through the blood from the tibia to the lung, undergoing 
small but critical changes en route. Moreover, examination of fixed MLM cells at 
rnetaphase indicates a non-murine origin, as  many metacentric and submetacentric 
chromosomes are visible; murine chromosomes are acrocentric. Histological distinctions 
(as wcll as differences in the in vidro experiments discussed b low)  suggest that MLM is  
a novel cell line which differs subtly from the parental MNNG line. An analytical 
chomosome spread of h e  MNNG and NU,M cells would allow a direct comparimn as to 
the differences in ploidy and chromosome m~rphology. 
Transduction and Selection 
Selection for NeoR gene expression became evident between the third and fourth 
days of incubation in media containing 6418 (one rnglml). Selective pressure was 
maintained for at least two weeks. Transduction with STK and IL2 seemed to occur with 
a similar efficiency; by the third day of incubation in G418. perhaps 10% of the ceHs 
remained adberent and viable. Transduction with vectors containing the BAG gene was 
significantly less efficient; typically by the second ro third day, perhaps 986 of tbe cells 
had died, indicating a low level of transfer of the neomynn gene. These results correlate 
with the reported titers generated by each vector producer cell line. Higher efficiency 
would be expected for supernants containing a greater number of viral particles. 
~ Y S  demonstrate gene transfer 
Successful transduction of osteosarcoma cells with the herpes simplex thymidine 
kinase gene of the STK vector producer cells was evaluated by a functional G@V 
susceptibility assay (Pig. 1). While this assay provides a g d  mems to determine the 
functionality of the transferred gene, it is not indicative of the prmise levels of Hs-tk 
produced by the cells, nor the number of copies of the gene introducd. This is a 
drawback in that the operative range of activity for a given concentration of the HS-tk 
enzyme is unknown. Ideally, a quantitative measure of the amount of enzyme produced 
daily by a given number of cells would be determined; however, there is currently no 
ELISA or other ilnmunoassay available for this purpose. In each case, however, the 
insertion of the STK gene resulted in a marked enhancerncnt of sensitivity to GCV. 
An enzyme-linked imrnunosorbent assay was performed on all 112-transdraced 
cell lines (fig 2). Each line was found to produce antibody-recognizable IL2 at clinically 
relevant levels. Differences between the cell lines lnay be related to cellular division, 
multiplicity of infectlon, avidity of the transcriptional apparatus, or secretory capacity. 
The non-IL2 transduced lines which were tested showed no significant difference in 
absorbance compared to the negative control. 
Transfer of the B-galactosidase gene was conlirmed on the basis of X-Gal 
histochemical staining (fig 3). The active, transferred enzyme cleaves the X-Gal 
substrate to a chrornogenic compound. A spectrum in color change is observed in the 
cells, from deep blue to no color change. This test is a good measure of gene 
incorporalion, as the intensity of color development is proportional to the amount of 
enzyme being produced. Four of the BAG-transduced osteosarcoma cell lines showed 
around 80% of cells as obviously positive for transfer of the gene. In  he G292 (BAG) 
line, less than 50% of the G418-resistant cells stained positively. The BAG arecbr 
producer line showed 91% of cells as positive. In theory, each of these cell lines, barring 
genetic drift of the vector, should turn blue to indicate transfer of the BAG genc. Cells 
evdua td  as negative may actually have been transduced, but are expressing only low 
levels of B-galrtctosidase, so that the color change is not apparenl with light microscopy. 
The differences m y  also relate to copy number. Also, there may be a range in membrane 
permeability of the X-Gal solution; cells absorbing relatively less of this chemical would 
be expected to starn less intensely. 
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Cmwt41 (table 1). The purpose of this assay was to obtain an estimate for 
the in vitro growth rate or each original and modified cell line, and to dekmine whether 
retrovird-mdiatd transduction with the various genes would induce a significant effect 
on this growth rate. Furlhemre, although in vipo and in vivo results cannot expwM 
to correlate exactly, an awareness of the proliferative rate is useful in accounting for 
trends observed in animal studies. 
Placing the cells in order of germeration time by transduction category within each 
cell line, the BAG-transduced ceils rank first in overall proliferative rate. The non- 
transduced and STK-transduced cells rank next, having the same intermediate relative 
position. IL2-transduced cells expanded at a slower overall rate. 
There are a number of possible explanations as to how ~etroviral gene transfer 
might affect generation time. Perhaps the most likely prospect relates to the fact that any 
given population of cells is plyclonal or oligoclonal. being comprised of several 
subpopulations which exhibit different molecular characteristics. The growth rate of 
these different subpopulations will bc likely to range along n continuum. As retroviral 
infection is largely a random process, the small percentage of' cells which survive 
selection may be considerably different from the bulk population, a scenario similar to 
"'bottle-neck" evolution. Thus, happenstance may be the pnmary governing force behind 
the mean growth rate of the cells that are selected. 
Several other factors may also affect the generation time. The site of integration 
into the genome of the target cell could have an impact. Integration near the promotor 
region or other regulatory sequences of genes involved in the cell cycle might dso affect 
growth rak. Interruption of genes in this family by the introclucd sequence could result 
in an increased growth fatc (if an inhibitory gene were affected) or a slower growth rate 
(if a gene directing cell cycle progression were altered). Of course, retroviral integration 
into the genome of the target cell is a nearly random event, and interruption of any gene 
at all, particularly those regulating the cell cycle, is unlikely to occur on a regular basis. 
Altered growth patterns could result from an interaction with regulatory proteins (like 
repressors). by effmting a shift in the transcriptional profile of the cell, or by causing 
to increase the expression of certain genes involved in I-epllcati~n; cell-to-cell eff~ct.53 
are also possible. These even18 could easily depend upon the conSormationa1 propelfies 
of the novel proteins, and might be amplified in multiply-tmsduced cells. 
It must be mentioned tbae in most cases, the growth assay was pefformed only 
once for cell line. Duplicate counts were done in each case, yet it would be 
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necessary to conduct this assay several more times to discern with confidence the subtle 
differences that may exist between the growth patterns of the various cell lines. 
However. definite trends have been identified. For example. each cell type from thrw 
osteosarcom lines (MWG, MLM, and TE85) all replicaled a a similar, relatively rapid 
pace (about 20-30 hours), which may reflect their common origin. Also, the 6292 cells 
grew signjf i~ntly slower than any other cell type (which may contnbute to the relalively 
erratic behavior of these cells in the other assays). This could indicate a fundamental 
difference which exists between osteosarcomas of disparate origin; also, G292 may have 
undergone alterations in various metabolic pathways which would necessitate the 
provision of some unidentified nutritional supplement for optimal growth. The trend for 
cells producing high levels of IL2 to grow at a more leisurely pace has been noted in 
previous studies, but most evidence appears to be anecdotal. 
In actuality, the growth rate of a polycloaal population of cells is likely to be 
highly variable and dependent upon both extrinsic and intrinsic factors. Such factors 
might include passage number (indeed, significant variations might be expected to arise 
by random mutation in a population of cells maintained over the course af several 
weeks), density at previous passage, length of lag phase, nutritionat considerations, and 
the swretion of growth s~timulamry and inhibitory factors. Some of these variables do not 
lend themselves to experimental manipulation. 
GCV-Sensitivity Assay (figs. 4-8). 
Specific comments are made concerning results for each cell line. This is 
followed by general comments concerning t h s  series of experiments. 
MNNG. The MNNG (STK) line was highly susceptible to GCV. A 98.4% 
reduction in growth was seen at the lowest concentration of GCV, and the inhibition rose 
to 99.58 at the highest concentration (p < 0.001 for DPMs between no GCV and each 
concentration of GCV). The MNNG (NV) tine also showed a susceptibility to GCV 
(19.2% decrease in proliferation at 2 pgiml to a maximum of 61.9% at 10 pgirnl). 
Transduction of the MNNG line with the IL2 gene seemed to have a slight protective 
effect; only a small propoition (2.68) of these cells died at a GCV concentration of 2 
pglml. Even at the highest tested conoenlratioo of GCV, only a 36.5% reduction in 
proliferation was observed. However, the differences between the wild type and 1L2- 
transduced line are not statistically significant due to the small sample size. 
MLM. The MLM (STK) line was also highly susceptible to GCV. At the lowest 
con cent ratio^ of GCV, a 99.1% decrease in proliferation was seen. At the highest 
concentsation, the decrease in proliteration rose to 99.75% (p < 0.001 for DPMs between 
no GCV and each concentration of GCV). The unmodified MLM line demonstrated 
some susceptibility to GCV (44.1% decreave in proliferation ak 2 yglml GCV up to 
68.9% at 10 pglrnl); the differences in DPMs between the replicates without GCV and 
those with 10 pglml GCV are significant to the 95% confidence level. The susceptibility 
of the IL2-transdud line ranged from a 23% deerease in proliferation at 2 pgtrnl GCV. 
up to 44.2% at 10 pglml, and the differences in DPMs between 0 and 10 p g / d  GCV are 
statistically significant to the 95% confidence level. The susceptibility of the IL2- 
trmsduced line is significantly (p < 0.05) less than that seen with the wild-type line. 
TE85. Like its derivative strains discussed above, the parental TE85 line d so  
showed high susceptibility to GCV when transdud with the STK vector. The decrease 
in proliferation ranged from %.% at 2 pglml to 99.4% at 10 pg/ml (p < 0.001 for DPMs 
between no GCV and each concentrzdion of GCV). The unmodil-ied line was somewhat 
less susceptible to GCV than those above (ranging from 17.4% at 2 p g / d  to 46.6% at 10 
pg/ml). The 112-trasduced cells were inhibited at a slightly hgher level than the non- 
tlansdueed cells (27% at 2 pglml, up lo 44.2% at 10 yg/ml). 
MG63. The STK-transduced cells of this osteosarcoma showed high 
susceptibility to GCV (99.1%) at the lowest concentration of GCV. The reduction in 
proliferation increased directly with GCV concentration (99.7% at 10 pglrnt; p < 0.001 
for DPMs between no GCV and each concentration af GCV; p < 0.05 between DPh& for 
2 and 10 pglrnl and between DPMs for 5 and 10 pglml GCV). The wild type cells 
showed a marginal decrease in growth with GCV (17.4% at 2 pg/rnl to 45.9% at 10 
pgtml). The IL2-transdud cells proved to be more prone to GCV-mediated demise than 
did the noo-lraasduced cells; the reduction in MG63 (IL2) cells ranged from 34.1% at 2 
p g t d  to 63.4% at 10 pglml (p < 0.05 between DPMs for 0 and 10 pglml). These cells 
were also the most sensitive to GCV of any IL2-transduced line. 
G292. This cell line showed lower levels of CCV-susceptibility cornpard to the 
other osteosarcornas. The STK-transduced cells showed a relatively low (87.7% to 
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93.7%) sensitivity to GCV (p < 0.05 for DPMs between no GCV and each concentration 
of GCV) The wild type cells showed a low level o l  inhibition lo GCV (21.56 lo 
353%). The IL2-traosduced G292 cells showed a modestly better survival pattern than 
did the unmodihed cells (7.9% decrease in proliferation at 2 pgiml to 27.1% at 10 p g h l ) .  
indicating that the IL2-traosduced cells were slightly protected from GCV-mediated 
iahi bition. 
All STK-transduced lines showed statistically significanl susceptibility lo GCV. 
All IfS-tk positive cells should be inhibited in the presence of GCV. Here, the highest 
rate achieved was I)9.75%'o. There are a number of possible reasons which might explain 
this minor discrepancy. In these experiments, cells were incubated with GGV for 414 
hours. Only cells undergoing DNA replicalion in this tlme span would be targeted. The 
fraction of remaining cells could represent a slow-growing subpopulation; a meandering 
replication rate would decrease the opportunity for incorporation of GCV-triphosphate 
into a growing DNA strand, and could prolong the survival of susceptible cells. This 
explanation i s  particularly likely to account for the substatidly lower susceptibility seen 
in the sluggish G292 line; with an average generation trme in excess of 80 hours, perhaps 
ody about half of the cells underwent replication during the incubalion with GCV (and 
some of the cell death might be accountable for by the bystander effect). Moreover, il has 
also been reported that GCV is catahlized slowly by cells,s5 it is possible that a longer 
incubation period would have induced greater inhibition. 
Furthermore, the radiolabel could have been expressed by dying cells that had not 
yet lost their adherence properties. In dher words, greater inhibition may have been 
achieved, bul not realized in the time allowed for analysis. The highest level used here is 
lower than the minimal serum level necessary for in vivv activity.85 Some cell types may 
be better equipped 10 recognize and sequester low levels of foreign substances. Higher 
efficiemy has been demonstrated by increasing the GCV conceatratlon (data not shown). 
Another possibility for the less-than-complete inhibition of STK-traduced cells 
is that a small fraction of the cells were CCV-resistant. This could ~ s u l t  from mutations 
in the HS-tk construct in a small number of celb, followed by rapid expansion of this 
subpopulat~on during selective pressure. Indeed. it is conceivable that t h s  type of event 
=curs infrsquently though regularly in vector producer lines. For example, random point 
rnuaons in the vector could render the tk-promotor ineffective or knock out a crilicd 
c&fi which would impair the function or the resulting protein; retention of the neomycin 
96 
resistance and packaging Wquences would allow ais  null vector to become incorporated 
into mget  cells This m e c h a ~ s m  could also be invoked to explain some d the ihnctional 
variability obsened with other vectors. GCV-resismce could also be a newly acquired 
trail stumbled upon by the molecular adaptability and g o d  tbrlune of an occasional cell. 
A limited su~epfibility (UP to 68.4%) was seen by HS-tk negative cells including 
each wild-type and 112-transduced o s ~ a r c o m a .  This 1s somewhat unexpected, in thal 
these cells have nut been engineered to express the gene for which GCV demonstraks 
preference. A possible explanation ul' this is low-level pbosphorylation of GCV by the 
endogenous tk gene or other cellular kinases. The selectivity of GCV for the herpes- 
derived enzyme has been reported to be twenty-fold greater than for cellular e n ~ ~ r n e s , ~ 5  
which would support this cxplmation. In fact, the cytornegalovirus has no tk gene but is 
destroyed by GCV due to other cellular kinases that produce GCV-TP.159 Alternatively, 
GCV may induce a dose-dependent cellular toxicity that is unrelated to replicalional 
interference. Previous work has shown that cell toxicity occurs in both HS-tk modificd 
and unmodified tumor cell lines, and this toxicity increases with duration and 
concentration of CCV exposure. 160 
When incubated in GCV, these two of the Sive cell lines (MLM and G292) 
showed a slightly decreased rate of inhibition of the IL2 cells versus the wild type cells. 
This trend was identified for each concentration of GCV tested, and the effect was 
generally diminished as the GCV concentration increased. Because the figures have been 
standardized, any difference in total proliferative rate is nullified. Thus, all else being 
equal, this protective effect is most likely attributabfe to IL2 production. Because this 
data was generated in viao, the cells were physiologically isolated from the immune 
system. As IL2 is classically considered to be a potentiating rather than a participatory 
molecule, this observation about IL2-transduced cells is somewhat novel. The IL2- 
prolective effect could be either intracelldar or intercellular, specific or non-specific, and 
may be inducible in gome cell lines upon challenge. Possible mechanisms for the 
i d u e m e  of 1 ~ 2  could include a direct interaction with GCV or GCV-TP, 
secondary induction of GCV-resisknce in selected populations, inhibition of celiular 
kinases, increased regulation of replication, or a generalized slowing of cellular 
replicatory p r m s e s .  Alternately, receptor-bound IL2 could trigger a cascade of events 
which influences GCV uptake. Of course, this effect was seen in only two of the five cel 
lines, md may or may not be represent a general phenomenon of tumor cells. 
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Except as noted, the differences in proliferation between the varying 
conccnlrations of GCV for no-vector lines are noi statistically s~gnificant to the 95% 
confidence level; the same is true for the ILZtransducd lines. Thus, it cannot be slated 
that the differences observed did not arise from chance or high oligoclond selection in 
G418. This limitation can be attributed to the low sample size (i.e.. triplicate). as well as 
the inherent variability in the experimental methnd. k r  example, in each well, the 
addition of a mere ten thousand cells was the goal, and each population of ce1h might be 
expected to incorporate the radiolabel at siightly different rates; the error is compounded 
by the fact that successive readings of the same filter mat a n  typically yield results 
which vary up to five percent. However, the trends discussed above are strong and 
uniform. It is likely that these trends would be statistically supported using a greater 
number of replicates. 
In Yitro Bystander Assay (figs. 9-13). 
In the absence of a bystander factor, it would be expected that only cells 
transduced with the STK gene would killed upon incubation with GCV. Thus, 
coincubation of MNNG (NV) and MNNG (STK) cells with GCV should result in a 
decrease in projiferation proportional to the number of MNNG (STK) cells present. For 
example, in a mixture having 8% MNNG (STK) and 92% MNNG (NV), only 8% of the 
cells would be expected to die, When this assay is performed, however, a 95.1% 
decrease in proliferation is observed, indicating that the vast majority of unmodified 
tumor cells are killed along with those which are STK-transduced, Because these 
twnsduced tumor cells are not packaging viral particles, the conferral of sensitivity to 
GCV must be mediated through a derived factor. 
Thus rat, the identity of the bystander factor remains unknown. The leading 
hypotheses were presented in the introductory section above, and will be addressed 
further b low.  Regardless of the composition of the factor, the erfect it mediates could 
have a profound impact on the applicability of gene therapy in the treatment of cancer. It 
would be very relevant in clinical trials to have an awareness of the strength of the 
bystander effect, and how much the faclor might be diluted before losing its antitumor 
activity. This in vl'tro assay demonstrates both the presence and the potency of the 
bystander factor. Here, a strong suppressive effect (86.2% decrease) is seen in a mixture 
conwining only 2% MNNG (STK) cells. Even as low as one petcent MNNG (STK) cell, 
a 46.68 decrease in proliferation is seen. This suggests that delivery of the STK vector 
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to cancer cells is not to induce a significant response. The ability of the 
factor to operate over a dlslance would have profound implications as a 
s~stermc therapy; this potential was explored in nude mice described below. 
The principle of this in v i m  assay was to explore the potential of STK-tranduced 
osteosarcoma cells to communicate a GCV susceptibility to wild type. cells. The potentjd 
for 112-transduced cells to enhance the bystander inhibit was also tested by co-incubaing 
these cells with STK-transduced cello and wild type cells. In the initial five assays, IL2- 
transduced cells were also used to target wild type cells without STK-kransduced cells, 
and as a control, STK-transduced cells were used to target IL2-tl-aasduced cells. A more 
stringent bystander assay was performed for the MNNG line; this assay tested only the 
effect of NINPJG (STK) cells and a mixture of MNNG (STK) and MNNG (IL2) cells 
upon the proliferation of MhTNG (NV) cells. 
For each cell tine, a decreasing percentage of STK-transduced cells resulted in an 
increased DPM. Thus, the bystander effect is greater with increastng concentration of 
STK-transduced cells. In each case, substitution of half of' the STK-tfarnduced cells with 
112-lransduced cells resulted in a lessened bystander effect, indicating that this 
phenomenon is not improved by the presence of IL2 fi>r these cell lines. 
The data obtained from these five bystander assays must be interpreted with the 
following considerations. In each case, the assay was performed in triplicate. Due both 
to the closeness in value of the figures and the small m p l e  size, the differences between 
three of the bur  expenmend groups (i.e., STK : NV, STWIL2 : NV, and STK : iL2) are 
not statistically significant at a given cellular ratio for each cell line. Likewise, because 
the values are so close to each other, the mixtures at the low end of transduced cell 
content (i.e., I%, 2%, 5%. and 10%) are not significantly different from one another. 
Indeed, a ratio of 1 % represents only 100 cells. which were transfeerred in a minuscule 
volume of 2 ~ 1 ;  the technicat aspects at this order of' magnitude make it difficult not to 
introdurn a level of error. Furthermore, because the assays were performed at different 
times with different s ~ k  solutions of tritium, it is not possible to directly compae the 
results &tween cell lines. 
For each ceIl line, however, the differences in DPM between 50% mixtures and 
the mixtures 10% and below are statistically significant (p < 0.05). The trends seen in the 
mixtures with the lower percentages of transduced cells are similar for each line, which 
infers a commonality. When the entire M y  of evidence is considered, a bend is firmly 
Moreover, when the bystander effect in the MNNG line was studied more 
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(uskg a four-fold greater sample size in each case), h e  resuits obtained were 
and were statistically significant to the 95% confidence level. This lends 
further ~ r d e n c e  tu the results of the other bystander assays. 
In some cell lines, the bystander e k l  appears to be enhanced by the presence of 
tumor cells which have been transduced with the IL2 gene. To investigate this 
possibility, MNNO (IL2) cells were coincubated with MNNG (STM) and wild type cells 
in mother series of experiments (table 9). There are two treatment philosophies from 
which these data may be approached. In the f~rst, a comparison is made between the 
proliferative effects in the presence and absence of MNNG (IL2) ceils at a gwen 
percentage of STK-transduced cells. This comparison is thrected at the mechanism of 
STK-mediated inhibition and the determination of whether this mechanism is enhanced 
through the presence of IL2-producing cells. En the second, the number of wild type cells 
is kept conslant, and the effects of a given percentage of traasduced cells (whether 
MNNG (STK) alone o~ an equal mixture of MNNG (STK) and MNNG (IL2) eelis) are 
evaluated. This approach is perhaps more practical. In a clinical selling, the number of 
transduced cells to be administered must necessarily be limited to a finite number; in this 
context, then, the ratio of tlzmor cells and transduced cells is fixed. Thus, it is important 
to determine whether the best response would be achieved using only STK-transduced 
cells, or a mixture of both STK and IL2-ttansduced cells. 
In these experiments, no synergy was seen between STK and IL2 tfansduced cells. 
At any given concentration of MNNG (STK) cells, there was no significant difference in 
the overdl decrease in proliferation whether MNNG (IL2) cells were present or absent. 
Thus, MNNG (IL2) cells, included in exchange for a like number of MIWG (NV) cells, 
did not cooperate with MNNG (STK) cells to induce a larger response. A direct 
comparison indicalev &at in five of the six mixtures, the inciusion of MNNG (IL2) cells 
actually resulted in a slightly greater survival, which may indicate that MNNG (I=) cdls 
are a less avid target than are the wild type cells. Fu&ermore, at a given ratio of MNNG 
(NV) cells, a significantly greater response was achieved by MNNG (STK) cells alone 
rather than by a mixture of MNNG (STK) and MNNG (IL2) cells. Thus, the presence d 
MNNC (IL2) cells detracts from the bystander effect in v i m .  However, these assays do 
not rule out an in vivo synergy between HS-tk and IL2, or a synergy in vigro in other 
tumor cell lines. 
1 00 
Establishment of In Vivo Tumor Models 
As a prelude lo animal studies, the first task was to determine which of the four 
original cell lines (IdNNG. TEES. MG63,6292) would produce growth in nude mice. Of 
these four lines, only MNNG proved to be tumorigenic. This is a human osteosarcoma 
line (Tm5) which was transformed in vim with a chemical mutagen (N-methyl-N-nitro- 
PJ-nitrosogumidine) to produce a highly malignant cell line. Ar both subcutaneous doses, 
large masses were evident within one week; these tumors grew rapidly until reaching a 
maximal allowable size (2x2~1 cm) by three weeks, at which time the mice were 
euthanized. In the tail-vein groups, all mice receiving MNNG cells developed 
subcutaneous tumors at the base of the tail; upon reaching critical tumor mass (3-6 
weeks). the mice were sacrificed and the internal organs surveyed for metastatic growth. 
This pilol experiment was also informative in that no mice were observed to show any 
detrimental systemic response to the xenografted cells, and in no case did the cancer 
invade beyond the subcutaneous layer. The characteristic of this cell line to remain 
localized when introduced subcutaneously allowed it to be exploited as u model for 
further experiments which are described below. 
Mice receiving implants of each of the other three cell lines (TE85, MCB3, 6292) 
failed ta develop tumors. In the subcutaneous groups, small nodules developed at the 
injection site, at a ssize proportionate to the m11 dose. The nodules were typidiy  cleared 
within a week, and in no case did the nodules expand to a sustained Eumor. No tumor 
growth was seen in any of the tail-vein groups. All mice were euthanimd after six weeks; 
nothing unusual was noted at autopsy. 
Failure of these ceHs to produce tumors is likely to be related to a combination of 
the following factom: slow growth rate, recognition and destruction by host defenses 
(including natural killer cells), or confrontalion by an inhospitable environment (lacking 
essential nutrients). Spontaneous bone tumors are rare in labratory mice.fi1 In a survey 
of 19, 875 mice kept under standard conditions for 18 months, only six osteomcornas 
were found.6 This indicates that the incidence sucb tumors is less than 0.18, and lends 
credibility to the a~sumption that the tumors that did develop were induced as a resuit of 
tumor cell implantation. 
safety 
The comprehensive picture provided by the in virw experiments discussed below 
ontr ibuks  to the luge body of evidence that the administration of vpc may be done 
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and without noticeable sideeffects. Proper delivery of these murine fibroblast 
lines? injected either intrat~l'kl~rdly or as mixtures with tumor cells, appeared to induce no 
untoward local or systemic reaction. Moreover, no differential in safety was seen 
between the STK, IL2. and BAG vpc (all modified mouse cell lines); all were equally 
well-tolerated. Control mice receiving separate subcutaneous inwula (1x10~) of these 
vpc showed only transient induration at the injection site, which suggests that these cells 
are not tumorigenic. Subsequent examination at the implant site showed no gross injury, 
and histological evaluation of the implant site revealed normal tissue. 
No mouse appeared to experience any ill-effects Prom the presence of retrovirus. 
This indicates that integration into no& tissue either did not occur or was not at all 
deleterious. No evidence of disease resulting from recombination to replication- 
competent virus was observed. 
irr vilro transduction of tumor cells with retroviral vectors followed by 
implantation of the altered cells had no added ill-effect upon the animals compared to 
implantaliua of unmodified tumor cells. Transduction with the EL2 gene actually was 
found to substantially decrease the tumorigenicity of the celts. This supports the tenet 
that tumor cells may be safely manipulated in v i a .  
The adverse response by some mice during the therapeutic course is most likely 
attributable to GCV toxicity. These mice displayed what came to be recognized a9 a 
"classic" syndrome involving anergy, weight loss, posterior hunching, lethargy, flaking 
skin, anJ. dehydration. Such symptoms are similar to those which have been identified as 
a toxic response GCV and are identical those seen in control mice which are given CCV 
at the same dose and duration (data not shown). These symptoms were most often seen 
during the second half of the twelve day CCV regimen, and typically persisted two to 
three days until death of the mouse. Some adjustments were made in subsequent 
experiments to minimize this morbidity by lessening the dose of GCV and isolating 
affected mice. However, affected mice seldom showed improvement, suggesting that 
serious pathology tcr the organ systems may develop in affected animals prior to any 
obvious outward sign. Previws work indicates that the conc&ntration and duration of 
GCV treatment used here are the minimum necessary to produce a strong therapeutic 
( d a ~  not shown) GCV-related mortality remained between five and ten percent 
throughout this study. 
102 
Cellular Thmshdd of MNNG Tumorigenieity (fig 10). 
Of the t ~ o u s a d s  of tumor Cell lines with which investigators work, type hat; 
unique i* viho and in viva growth characteristics. Cell lines differ in s p i e s  of tropism; 
for example. tumor cells derived from a given strain of mice typically will not grow in 
other strains. However, many tumors from other species will grow within the 
immunologically hospitable environs of the alhymic mice. Cell lines also differ in organs 
of tropism, Cells from a similar line often show different patterns of growth when 
introduced to various organs within the same animd model. For example, it has k e n  
reported that a Count of 4x104 human osteosarcorna (KRIB) cells are sufficient to 
prdrace a tumor when injected intraos~eously;~62 over twice this number of MNNG cells 
are necessary to induce a subcutaneous tumor. Other lines may only grow at a limited 
~ u n h e r  of sites. Finally, tumor lines may differ drastically in the number of cells 
required to produce tumors. To illustrate this, a rat mammary carcinoma (MATB) will 
grow progressively and kill experimental animals within three weeks when as few a.s 
1 x 1 6  cells are intnduced intraperitoneally,l43 while other lines are not turnorigenic at 
any practical dose. 
Progressive growth in nude mice of xenogeneic tumors is influenced by tumor- 
related properties, such as the origin and type of tumor, and on the route of' 
inoculation.'45 It is reported that human melanomas, sarcomas, and soft-tissue 
carcinomas can be transplanted successfully to nude mice, while other carcinomas 
(breast, prostate, stomach) are more difficult to establish.1b4 Once ensconced, the growth 
rate of tumors may depend largely upon the ratio of proliferating cells to dead or dying 
cells. Tumor growth is also dependent upon mouse-related factors, such as the q e ,  
and state of health. 165 Additional factors influencing tumor growth are 
extracellular matrix production, edema, bleeding, and necrosis.l6Vufihermore, within a 
human t u r n  transplant, only the neoplastic cells are of human origin; the connective and 
vascular tissue are derived from the mouse host.167 A component of the variability in 
tumor may depend upon the exwnk of recruitment by individual tumors. 
This variation in experience with different tumors was the rationale behind 
the cellular threshold required for MNNG cells to form tumors ~uubcutanmusly. 
Injection of ~ ~ 1 0 4  cells resulted in no tumor growth; twice this number resulted in tumor 
in some (17.6%) mice. When at least 2 x 1 6  MNNG cells are injected 
s u b c ~ n e o ~ s l y ,  dl mice, without exception, develop tumors which have the capacity for 
progressive growth. This trend approximaks the classical sigmoid curve and plateau 
expected for 
cell number 
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such studies. F m  this data, and assuming a linear relationship between 
and tumor development, the TD50 (cell number required for tumor 
development in 50% of animals) would be approximately 1 . 6 1 ~ 1 0 ~  MNNG cells. 
Knowledge of the in viva grow~h threshold was instructive in designing subsequent 
treatment protocols. 
MMul.es of MhTNG and STK vgc (fig 15). 
This experiment was designed to determine whether retroviral-vector mediated 
gene therapy codd, under optimal conditions, result in ablation of subcutaneous MNNG. 
The treatment was idealized both in the interval of vpc introduction and in the equal 
distribution of vpc among target cells. Mce in each of the four experimental groups 
received 1 x 1 0 ~  MNNG (NV) tumor cells mixed with five times as many. twice as many, 
equal numbers of, or half as many STK vpc. Over the next seven days after implant, the 
vpc produced a continual supply of the HS-tk vectors. These retroviruses served as the 
vehicle for in vivo transduction, whereby the tk gene was insinuated into the DNA of 
neighboring MNNG cells. Through the existing transcriptional and translational 
machinery, these tumor cells now began producing the enzyme that would make them 
susceptible to elimination by GCV. 
Mice in Group 1 received a totat inoculurn of 3x106 cells subcutaneously, at a 5: 1 
ratio of STK vpc to MNNG tumor cells. Immediately prior to the first GCV injection on 
day 11, all animals had developed spherical tumors with a maximal diameter of 7.4 +1- 
2.9 mm. The first significant decrease in tumor size was noted three days later, when the 
average maximal tumor diameter had dropped to 6.2 +/- 1.6 mrn. Thereafter, the tumors 
shrank rapidly. By the final day of GCV, the tumors had resolved to a maximal diameter 
of 1.75 +/- 2.75 mrn, and were flat and scarlike. Two mice &ed during GCV treatment 
(on days 19 and 23). One of these mice had no residual tumor by day 20; the other three 
were cured by day 34 (2) and 49. Surviving mice were monitored through day 85 (at 
least six weeks after tumors were reported to be fully absent.) Mice receiving this ratio of 
cells and no GCV experienced progressive lumor growth. 
Mice. in Group 2 received a total inoculum of 1.5 n106 cells (half the number of 
Group 11, at a 2: 1 ratio of STK v p c  to MNNG cells. By day 11, the tumors had grown Lo 
a mximal diameter of 8.6 +I- 3.68 mm. The tumor regressed at a similar pace to those in 
group 1. TWO mice showed no evidence of tumor near the end of GCV (day 20 and 22). 
The other three mi= retained small but measurabIe wars until day 64 and 72 (2). D u ~ n g  
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the two week follow-up until day 85. these animds remained healthy and tumor-free. 
Mi- receiving this ratio of C C ~ ~ S  but no GCV experienced progressive tmlor growth. 
In Group 3, mice received a total inoculum of 1 x 1 0 ~  cells, at an equal ratio of 
STK vpc to MNNG cells. By day 11, the average maximal tumor diameter was 8.8 +I- 
3.6 mm. These tumors also declined in size rapidly; all residual traces had disappeared 
from individual mice by day 22- 37, 57, and 75 (2). No regrowth was noted. Mice 
receiving this ratio of cells but no GCV experienced progressive tumor growth. 
Mice in Group 4 received a total inwulum of 7 . 5 ~  105 cells, of which 67% were 
MNNG tumor cells. By day 11, the average maximal tumor diameter was 7.2 +/- 3.3 
mrn These mice required a longer period of time to becorn tumor free. One mouse died 
during GCV injections (day 21); one mouse showed no evidence d tumor by day 57, and 
another by day 75. The other two mice retained small, non-neoplastic scars until the 
experiment was terminated at day 85. Conlrol mice receiving this ratio of cells but no 
GCV experienced progressive tumor growth, to a maximal diameter of 20.33 +I- 3.8 mm 
by day 28. 
Between each of the groups, no significant difference was seen between maximal 
tumoa size by the first. day of GCV treatment, despite the over ~ix-fold range in initid 
tumor burden. Furthermore, no significant differences were seen between the maximal 
tumor diameters observed in any of the control animals. Because the difference between 
the groups was the number of STK vector producer cells, it may be ~nfesred that these 
murine cells are less tumorigenic than are the malignant human ostmsarcoma cells. The 
rate of tumor killing and clearance also did not differ significantly between the treatment 
groups. Tumors were consistently ablated with a 1: 1 ratio of MNNG cells to STK v ~ ;  
the retention of &nuk scar-like patches in two mice in group 4 makes the smaller ratio 
somewhat less reliable. No mice showed regrowth during the fbllow-up period. 
Mixing tumor cells with therapeutic cells prior to tumor implant does not 
approximate a treatment scenario; indeed, the glory of success here is analogous to that of 
a eonstnrction crew demolishing a building made of explosive bncks. However, it was 
imperative to ascemin whether these tumor cells would be at all amenable to our gene 
therapy strategy. In some cases, tumor cell lines have k e n  sufficiently belligerent to 
gmw progressively despite co-inoculation with vector-producing cells168 Here, one 
MNNG cells were with ;IS few iu 5x105 therapeutic cells. A( this 
ratio, it is likely that less thm 100% of MNNG cells became t raduced wlah the tk gene, 
and the "bystander effect" quite possibly Was integral. 
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These data do suggest that the growth of unmodified MNNG tumors may be 
sIightly inhibited by the administration of GCV; the linaE maximal diameters of these 
t um~rs  were 19.5 +/- 1.6 mm for mice receiving GCV versus 23 4-1- 2.5 mm for mice 
receiving saline. Although the error bars overlap slightly for this comparison, it is 
possible that this trend would be borne out with a greater sample size. This observation is 
consistent with in vilpo data. and suggests a low-level of phosphorylation of GCV by 
cellular lunases resulting in decreased tumor growth. 
As was notd,  several mice retained a residual inflammatory "scar'Vor a number 
of weeks after completion of GCV injections, and the diameter of such scars was 
included in data analysis. Histological examination of representalive s a c s  obtained from 
mice which made early departures during the experimental course suggested that this 
tissue was fibrous connective infiltrate, much different io appearance thm sections 
through living tumors. In a11 but two mice (both in Group 4), this warlike tissue was 
eventually cleared away, leaving the original injection site unblemished. 
In V i m  Bystander Experiment (figs. 16-18). 
MSdNG osteosarcoma e l l s  display a potent byshnder effect in vivo, A mixture 
containing as little as five percent STK-transduced cells was sufficient lo result in 
compiete and lasting tumor in all experimental animals. The bystander effect appears to 
be enhanced by the mutual presence of MNNG (IL2) and MNNG (STK) cells; when as 
few as 2.5% of each are ca-injected with wild type tumor cells, all mice were cured. 
Regression of tumor mass typically began on the third day of GCV treatment. The time 
frame of regression was correlated with the cell mixture received. 
Of mice receiving mixtures of M N G  (NV) and MNNG (STK) cells, 978 
(3435) were cured folIowing GCV treatment and many of these mice (29/34) were cured 
by the 28th day of treatment. Control mice receiving lYZNNG (NV) a d  MNNG (STK) 
cells and no GCV showed a slightly delayed expansion of tumor size compared to mice 
receiving only MNNG (NV) cells, probably owing to a slower growth rate or decreased 
tumorigenicily of the STK-transduced cells. 
Of mice receiving mixtures of G (IL2) and MNNG (NV) cells, 758 (15i20) 
were cured following CCV treatment. The cure rate was dependent upon the ratio of 
cells administered. The 112-mediated effects began to wane at a ratio of 12.5 : 87.5, (46 
curd) and dmpped sharply at ratio of 5 : 95 (one of five cured). Of mice receiving 
G (NV) and MNNG (IL2) cels  and no GCV, 50% (five of kn) were prmanently 
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cured of tumors. Thus, the ability of IL2tranduced cells to mediate tumor regression 
increased significantly in groups receiving GCV. Because the IL2 gene produd is not 
known to inbract with GCV, this difference was somewhat surprisiag. No sig~ficant 
difference in tumor growth rates was noted between groups where GCV was the 
differential parmeter. Possibly. CGV acts as a hapten which further activates the 
immune response in the presence of IL2. Alternatively, soluble IL2 may activate a 
subpopulation of cells to GGG susceptibility (possibly by altering the transcriptional 
profile o l  these cells), 
Tumors comprised of MNNG (NV), (STK), and (IL2) vvere cured with the 
greatest efficiency compared to other groups. One hundred percent of mice were cured at 
aU levels of wild type tumor content up to a ratio of 95 : 2.5 : 2.5 (N = 41). Even when 
only one percent ol the total tumor cell inwulum was comprised of therapeutic cells, 43% 
(two of five) mice were permanently cured. Tumors containing fractions of both MNNG 
(STK) and (IL2) ceHs dong with MNNG (NV) cells grew to markedly smaller volumes 
than did tumors containing similar fractions of only MMVG (STK) and (NV) cells. For 
example, the implant of MNNG (NV) and W C  (STK) cells at a ratio of 87.5 : 12.5 
(Croup 10) attained an average maximal volume of 66.71 mm3; when MNNG (NV) cells 
were mixed with the same number of MNNG (STK) ce11s along with W G  (IL2) cells, 
or a 75 : 12.5 : 12.5 ratio of each (Group 8), the maximal tumor volume attained was over 
eleven-fold less (5 6 rnrn3). Even tumors containing 8'7.5% wild type cells mixed with 
6.25% each MNNG (STK) and MNNG (IL2) (Group 11) grew to an average maximal 
volume (6.4 m 3 ) ,  over ten times less than of the tumors with 87.5% MNNG (NV) and 
12.5% MNNG (STK). fistulogical examination of tumors isolated from control mice 
suggested no significant difference in appearance between tumors derived of the various 
cell combinations. 
The enhanced in vivo tumor-killing capacity of STK and IL2 in combination may 
result from at lea& three general mechanisms. First, each gene product may act singly to 
inhibit tumor cells, and the overall effect woukd be the sum of each ind~vidual 
eontribulion. Secondly, there may exist a cooperation between the two components, 
whereby the composite antitumor effect would greater than the sum of the p a s .  A third 
possibility is that a synergy exists between tbe STK and IL2 gene poducls, whereby each 
potentiates the other to more efficient activity; in  tYs case, the overall effect would be 
multiplicative. Additional research is being pursued to elucidate the operative 
mechanism, 
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Overall. tumors containiog 113 cells required significantly less time to disappear. 
Of all mice which were cured, mice receiving mixtures of MNNG (STK) and (NV) cells 
(N = 34) took an average of 25.2 +/- 3.4 days to be cured. Mice receiving both MNNG 
(STK) and (ILZ) cells along with (NV) cells (N = 36) were cured after ao average ol. 19 
+/- 2.9 days. Responding mice which received MNNG (IL2) and (NV) required an 
average of only 18.6 +I- 3.7 days to become tumor-free. The enhanced rapidity of 
ablation of' IE2-containing tumors is likely to be reiated to the heightened immune 
response induced in these mice. NK activity, which is noi depressed in athymic nude 
mice, would be expected to result in the direct attack of tumor cells, speeding the 
destructive process, Stimulation of phagocfic wlIs would increase the clearance rate of 
dead cells; in the absence of this stimulation, dead cells may linger at the tumor sib and 
make continued contribution to the tumor volume. Also, tumors containing 1U tended to 
grow to smaller maximal volume, and a smaller burden would logically be eliminated 
more quickly. 
The presence of IL2-tran&uced cells in the induced tumors had a significant 
effect on the growth of the tumor mass. Of the mice that received a 2x406 cell inoculurn 
of only W N G  (IL2) cells. 258 (two aC eight) failed @ develop any tumor. The other 
mice showed only minimal growth (average maximal volume of 3.1 mm3) followed by 
rapid ablation (six of seven showed no tumor by day 21). Of the three mice receiving a 
larger inoculum (5x10~) of MNNG (IE2) cells, each displayed small tumor growth 
(average maxiinal volume of 5.2 m3) followed by rapid ablation (no tumors by day  18). 
This general effect w a  noticed both in the presence and absence of GCV. Even when 
only the itnoculum contained only a small fraction of IL2-transduced cells, a significant 
reduction of tumor growth was observed. When a 9515 ratio of MNNG (NV) to MNNG 
(IL2) cells was introduced, the maximal growth was only 13.9% of the gmwth of MWNG 
(NV) cells alone (60.3 mm3 versus 432.8 mm3 at day 18.) 
Among the mice not cured, tumor progression was typicdly much slower in mice 
receiving 112-transduced tumor cells. For example. in comparing control groups 21 
(NV75 : STK25) and 23 (NV75 : IL2 25), a significant difference (p < 0.05) was seen in 
the tumor volume. Tumors by day 46 in the EL2ucuntaining group had grown to  an 
average volume over 53 times less than that of the STK-containing group (8.7 mm3 
versus 4 5 . 7  -3). Moreover, the substitution of 10% MNNG (IL2) tumor cells for wild 
type MNNG cells resulted in a significant (p < 0.05) difference in average maximal 
volume (13.2 rnm3 versus 576.2 mm3) and slight arithmetic growth as opposed to 
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geometric growth. The reduction in tumorlgeiucity of highly d i g n a n t  cells by ILZ 
transduction is phenomenon which has been previously noted.130 This concept has 
important implications for the development ol autologous vaccines by ex vivo 
manipulation of existing tumors. 
The appearance of regrowth in a minority of a n i d s  probably occurred due to thc 
persistence of a small (usually nonpalpable), lucali~ed congregation of resistant tumor 
cells. These cells may have been somewhat isolated from responsive cells, or may have 
represented a dormant subpopulation which escaped eradication by virtue of a slow 
growth rate. Many of the mice receiving lL2-transduced cells alone showed some 
temporary regression. This is probably due to the activation of an (NK-mediated) 
immune response which was not potent enough to cope with the entire Lumor mass. 
The results reported for this experiment aclually represent two prolocoIs, the 
second of which was begun three weeks after the first. Initially, only those groups which 
had tumors comprised of at least 12.5% therapeutic cells (as well as the control groups) 
were undertaken. Groups from which the most interesting results were expected were 
assign4 a greater number [ten or eleven) mice. The overwhelming success within these 
groups prompted the addition of further groups (13, 14, 15, 18, and 19) which explored 
the applicability of therapy to tumors comprised of a lower ratio of' lransduced-to-wild 
type cells. Due tu constraints on time, space and animal availability, these groups 
contained fewer mice. 
Double Tumor Experiment (figs. 19-23) 
The design of this experiment approaches a more clinically practical scenario, 
representing an autologous therapeutic vaccine. In the future, it may be possible to treat 
patients having diffwe, unapproachable, or melastatic cancers by surgically resecting as 
much of the tumor mass as possible, then reintroducing tumor cells which had been 
altered en vivo $0 target remaining neoplastic foci. 
This idea of a "magic bullet" for cancer was first proposed by Erlich over a 
century ago, and the concept has since undergirded decades of work i n  the realm of 
iawnunotherapy. Approaches such as tumor-antigen specifxc monocEonal antibodies have 
been promising in thwry bul disappointing in practice. Genellc therapy may wwn offer 
the means to specifically target cancer by allowing the body to fully harness its own 
inherent protective mechanisms. Autologous tumor cells would have the advantage of 
escaping recognition as foreign intruders, by virtue of the self-speci flc antigens hey 
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Such cells. inbduced syskmically, mjgbl also be expected to rehluo their 
programmed capacity and thus become distributed to ihe more deeply 
entrenched sites of rnet-astatic disease. Ideally, this could offer a direct means to affect 
inaccessible ne0plaStic foci, andogous to a cellular Trojan horse. By 
trmducing the cells with genes which would bolster the immune respnse to allow 
recognition of the malignancy, or with genes which could coder a susceptibility to other 
a@nts, a dramatic response might be achieved. This approach bas the 
Potential to be more universally applicable and less invasive than direct injection of cells 
(foreign or autologous) into a single tumor mass. 
In this experiment, MNNG (NV) cells were initially implanted subcutaneously. 
One week later, a second inmulum was introduced at a distance of about one cm from the 
first tumor; this second implant was derived of transduced hANNG tumor cells whlch 
expressed either the tk gene or the IL2 gene. These modified tumor cells could 
potentially initiate a patent and specific immune response (in the form of expanded 
natural killer cell activity in athymic mice). Alternately, a soluble '"bystander factor" 
might be released from (he STK-transducal cells and communicated to the umodified 
cells. rendering them susceptible to GCV. 
Of the twelve mice in Group 1, 11 (92%) showed significant (p < 0.05) regression 
(i.e., at teast a 50% reduction in tumor volume) as a revult of a secondary MNNG (STK) 
tumor and GCV treatment, three of the mice showed over a 90% reduction in tumor 
volume. Overall, these mice demonstrated a 60.7% reduction in tumor volume, from an 
average of 552.5 +I- 258 cubic mm at day 19 to an average of 217.2 +I- 58.9 cubic mm at 
day 25. Because the mice expressed a variety of response intewds (i.e.. some tumors 
ng in size while others were rapidly shrinking, and some were regrowing at the 
m time that others were regressing), the average of the data is somewhat less dramatic 
than had all mice responded simultaneously. Generally, though, the average tumor 
volume continued a pattern oL increase during the first six days of GCV treatment, then 
decreased abruptly during the second six days. In the week following GCV treatment, 
seven of the ten surviving mice had begun to show regowth of the primary tumor; by the 
end of the second week. the tumors other three mice had also begun to regrow. By day 
41, dl tumors harl expanded back to an average volume of 498 +I- 213 cubic mm, a level 
not significantly different than the average maximal volume prior to treatment. 
Histological exarmnation showed tumor cells which closely resembled the parental 
MNNG cell line. Inflammatory infiltrate and dcbris were visible around the tumor 
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buf s m u n d i %  tissue appeared to be non-necrotic a d  non-neaplastic. 
Significmt evidence of prllWUy tumor regression was also seen in Group 2, which 
received a secondary implant containing an equal mixme of WNC (STK) a d  ~ p ~ j q ~  
( I L 2 )  cells. The p d  average volume of the primary tumor (550 +/- 227 cubic -) was 
seen on day 41; by day 49, the average diameter had dropped 60.4% (218 +/- 107 cubic 
m). This regression was identilied at a later time frame than that scen in Group 1. 
Actually, nine of 17 (53%) of informative animals did show a major (over 50%) 
regression in tumor w h m e  dunng the second half of GGV treatment. Of the early 
respadere, 5 (56%) developed subsequent regrowth as early as day 34. Six of 17 mice 
(35%) showed a delayed response between day 25 and 41, ostensibly due Lo the action of 
1 Five of the seventeen mice (29%) showed no significant response at any time. 
The two mice that were cured both had developed moderately-sized tumors (25.23 
and 26.18 cubic mm) by day seven. Each mouse showed a response during both the 
GCV period (78.8% and 40%). slight regrowth (50.6% and 34.4%), then complete 
&sappearance of the tumor between days 41-49, 
In Group 3, all six mice received a secondary implant of h4NNG (IL2) cells. 
Among these mice, the total average reduction in tumor size was 63.18 (745.9 +/- 356 
cubic mm to 275.3 +/- 357 cubic rnm); the most drastic decrease (95% of the tolal) was 
seen between days 28 and 34. Ido Blouse showed a significant antitumor response during 
the course sf GCV ~njection. With a larger sample size, this relationship may have been 
more significmt. 
Interestingly, two of the twelve mice receiving secondary MNNG (STK) cells still 
retained a significant tumor mass (105 r n d  and 25.7 mm?), and a third showed a small 
s cd ike  residuum. This may indicate the selection of a resistant population of MNNG 
(STK) cells, or it may ~igni fy  differences in response capacity between sibling mice. 
Among Jnice in the other treatment groups, secondary tumors (consisting of 50% or 
100% MNNG (I=) cells) dissipated quickly and completely, invanably by day 41. 
This dab i d e a t e s  that MNNC (STK) and MNNG (IL2) celis are each able to 
independently effect a signrficant regression of an unmodified, previously established 
MNNC tumor. When used together, the two gene products appear operak with an 
effect, allowing some mice to be cured completely. The two vector products 
appear to act afcording to discrete time intervals. The STK principle mediates an early 
effect, the latkr part of GCV treatment (mean impact date = 22). The IL2 
principle mediares a delayed effect. clearly after the GCV treatment pefiod is over (meao 
1 1 1  impact date = 32). The distinct time frame within which each principle acts corroborates 
the logical inference that each functions via a separate mechanism. The in vivo 
transduction of wild type cells with the STK gene makes them susceptible to killing 
during the early period in which the actlve drug is provided. On the other hand. 1L2 is 
likely to operate both nonspecifically (by inducing a generally enhanced state of 
immunity) and specifically (by making 112-secreting tumor cells better recognized targets 
for the immune response). Tbe delayed effect seen with the introduction of 112-secreling 
cells is likely to be related to the amount oT time needed to tnduce a specific immune 
response, largely dependent upon the generat~on and mabilization of natural killer cell 
populations. The two mice that were cured in this experiment appeared to benefit from 
both rnechanlsms. 
It has been suggested that the two principles m y  interact synergistically to result 
in a more efficient tumor ablation. This Interaction could enhance the "bystander effect." 
Historically, it has been shown that ILZ, through a positwe feedback mechanism, induces 
an increased expression of IL2-receptors on the surface of the cells kt affects. Should 
uptake of the bystander factor be mediated at least partially through tbls receptor, better 
delivery and a more efficacious activity would be expected. Moreover, the presence of 
IL2 may somehow increase the half-life of the bystander factor, affording it more time to 
communicate itself to targeted osteomrcoma cells. 
Because of the progressive growth in tumor size among the mice receiving a 
secondary MNNG (BAG) implant, it can be confidently asserted chat the anti-tumor 
response derives from the specific gene encoded by the vector, rather than something 
inherent in the rnurine fibroblasts into whch the vectors are packaged. Moreover, X-Gal 
staining of the primary tumors in these a n d s  was wholly negative. This indicates that 
neither the BAG gene nor appreciable levels of the enzyme are transmitted from cell to 
cell. It is not surprising that the vector-producing cells have a limited range which the 
viral particles are aMe to amess. By extension, (he response seen by mice lo therapeutic 
groups must occur by some means other than cellular ~ransduction. 
Thus, it would seem that the MNNG (STKf cells may be producing some 
substance which 1s transmitted over a daslance to neighboring tumor cells. Ikwever, this 
$actor is nut able to deliver itself to a sufficient number of the unmdf ied  cells to mediate 
a complete and lasting cure. In the presence oC IL2, higher efficacy is seen. Changes in 
tumor morphology provided some insight as to the events taking place. Primary tumors 
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were generally ovoid and symmetrical during initial gmwth; in some cases, more 
~ r o n o m m d  regression was seen in the side proximal LO the secondary tumor. i though 
this observation constitutes a stat i s t id ly  inert perceptual discrifi nation, it does bring 
evoke the i m g e  of a bystander factor which is either labile or unable to penetrate to the 
distant side of the tumor mass. 
Much atlention has recently been afforded this "bystander factor." The 
phenomenon of tk-negative cells becoming susceptible to GCV along with tk-positive 
cells has been identified in a number of experimental models, yet at the present time its 
identity remains elusive. The factor may simply be activated CCV trighosphate which is 
passed through cellular junctions or taken up fromapoptotic cells. In this case, the 
bystander effect would be alun to a metabolic cooperation whereby cells, not themselves 
expressing thymidine lunase, acquire the means of their own destruction through the 
catabolism of tk-positive cells. Altemafively, the bysmder factor m a y  be a distinct 
macromolecule which is formed in tk-positive cells. 
The data here afford only an ambivalent answer lo the question of HS-tWIL2 
synergy. In vilro, a definitive argument against HS-tkllL2 synergy for the MNNG cell 
line is seen; here, the presence of LL2 does nol. significantly enhance the effect of STK- 
mediated killing. In vivo, both vectors generate a specific anti-tumor response which is 
enhanced when both components are present, The temporal difference in action is 
suggestive of two distinct, cooperative mechanisms rather than a unified, synergistic 
mechanism. The lack of correlation between in vilro and in vivo data implies that the 
immune system is of paramount importance lo the HS-tk/lL2 interplay. 
Paradoxically, recent in viiro work suggests that, unlike some other cell lines, 
MNNG does not produce a soluble bystander factor. For yome cell Iincs. the transfer of 
mecfiat from STK-transduced cells results in a substantial decrease in the proliferation of 
wild type cells; this has not been found to be the case for MNNG cells. ~ l t h o u ~ h  this
seems to be contradictory, b t h  sets of results could easily be accurate given the 
differences between in vivu and in v i m  models, In any case. the topic merits further 
research. 
Treatment of Established Osteosarcomm (figs. 24-30). 
The treatment of cancers by direct injection of vjx may prove to be a potent 
application of gene therapy. This approach is especially suited to localized tumors. 
Clinical triais are currently underway for the treatment of brain cancer. Many patients 
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with osteosarcoma could be excellent candidates due to the typical course and nature oS 
the disease. especially the metastatic component The cure rate of current therapies for 
osteosarcoma are less than ideal, and often entail the inestimable morbidity of losing a 
l imb Spread of the cancer to the lung or another bone is a significant problem. 
Successful gene therapy for oskosmoma could be an enomously satisfying alternative 
for patients in that it could selectively destroy the metastatic disease and preclude 
amputative surgery. 
The evaluation of this approach in animals is a necessary step in the process of 
gaining approval for new methodologies in medical practice. In working with bone 
cancer, the ideal scenario would be the induction and treatment of cancer cells which are 
localized in the bone. However, nude mice are small and naturally frailer than even 
normal mice; their long bones are similar in size and durability to dry toothpicks. 
Moreover, these animals are not especially tolerant of repeated invasive procedures. For 
these reasons, our treatment model used subcumeously induced osteosarcumas, 
Trial One (fig. 24). In this experiment, 40% of mice (four of ten) receiving an 
intratumoral implant of STK vpc showed a significant reduction in tumor size; 33% of 
mice (three of nine) receiving an intratumorai implant oC IL2 vpe showed a significant 
response; 11% of mice (one of nine) receiving combination treatment wcre cured 
completely. 
Of the responding m c e  which received STK v p c  (Group 1: fig. 25), treatment 
with GCV appeared to exert an early influence. Between days 14 and I 8  (corresponding 
to days 2-6 of GCV injections), the maximal tumor diameter remained relatively stable, 
around 15 mm. By day 19 (corresponchng to the seventh day of GCV), each responding 
animal showed a drop in tumor diameter, and daily measurements tracked a downward 
trend for the next eleven days. In contrast, the tumors in the CCV-negative subgroup 
continued to grow progressively. The response in this group was osknsibly due to the 
inhibition of the population of tumor cells which had been transduced with HS-tk . 
Of the responding mice whrch received IL2 vpc (Group 2: fig. 26), a similar 
plateau in tumor diameter was observed from days 13 to 18, followed by a significant 
shrialiae (78%) occurring from day 20 to 29. The nonresponding rmce which received 
GCV showed a slower progression of tumor growth compared with the GCV-negative 
subgroup. Because 1L2 and GCV are noL known to act upon one another, it was expecked 
that the tumors would show a similar growth pattern regardless of' the prevence of GCV. 
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The panial respome of some tumors to GCV was somewhat surprising and 1s probably 
r e l a d  to the presence of naturai fnurine Enases. 
of the tea mice that received STK and IL2 vector pmducer cells (Group 3: fig 
27). only one showed a significant reduction in tumor size. The responding mouse was 
cured of its tumor during the first four days of GCV administration. Although it is 
difficult to generalize from a single animal. this mouse did have a smaller tumor prior to 
GCV treatment (the maximal diameter was seven mm, on day I I). This may indicate that 
a favorable outcome is more likely when a small or slowing growing tumor is treated. 
Also, due to its smaller hunor, this mouse may have benefited from a better delivery of 
vpc. The nine nonresponsive mice showed progressive growth, but at a significantly 
lower level than the mice which did not receive GCV. 
Mice in Croup 4 were controls for the effect of the vector. The introduction oi the 
8-gdactosidase gene is experimentally null and would not be expected to have any 
therapeutic cffect. Thus, this group was included to show that the response seen with HS- 
tk and fL2 vpc was a direct consequence of the protein trmslated from the inserted gene 
rather than a nonspecific, inherent effect of the rnurine fibroblastic cells. Moreover, the 
efficiency of transfer of the BAG gene can readily be determined by X-Gal ~biniflg. 
Mice receiving BAG vpc and GCV did show a significant (p < 0.05) reduction in tumor 
diameter (55.8%) versus mice receiving BAG vpe and no GCV.  ~ h i v  is presumably due 
to low-level phosphorylation of GCV by cellular bases. 
This experiment was actually the first to be attempted, and because of this, the 
growth parameters of MNNG had not yet been characterized. The original inoculurn of 
5x1@ was twenty-five times the minimal inoculum needed to consistently induce tumor 
formation; thus, this protocol represented a more formidable treatment challenge than 
may have been necessary. By day five, when the vector producer cells were injected, the 
tumors were typically peanut-sized, which is proporlionately enormous far a 20 gram 
anlnal. Extrapolating from the determination of growth rate in vitro, the MNNG cells 
would have had sufficient time for five replication cycles, meaning that the initial 5 
lnillion mils may have expanded to over 160 million cells by the time of vpc injection. 
Of course, in v i m  growth cannot be expected tu correlate exactly when presented with 
the added variables of gmWh in an exprimend a n i d ,  but these flgures are probably a 
~asonabh approximation. A tumor of this mass is likely to have a substantial effect on 
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the general health of an animal, making it less amenable to treatment and less able to 
mount a proper immune response. 
Eurthemore, the injection of 15 million vpc per t u m r  approaches the tinzit for 
the volume that may safely and effectively be injected without damaging the &in or 
introducing a cellular embolism into the vasculature (which is enhanced around the 
tumor). As would be determined subsequently in the first mixture experiment (when 
MNNG eelis were co-injected with STK vpc), at least a one-to-one ratio of tumor cells to 
vector producer cells is necessary for the therapy to be fully effective. Here, the ratio of 
MNNG cells to vpc was perhaps as high as ten to one. Moreover, the mixture has the 
advantage of approximating optimal delivery, whereby tumor cells and vpc are evenly 
dispersed, increasing the opportunity for ia vivo transduction. Here, efforts were made to 
inject the vpc throughout the tumor (two injection ~racts were used to m e s s  both sides of 
the tumor mass), but there is no evidence that the therapeutic cells are capable of 
uniformly infiltrating the tumor. Discrete areas of the tumor whreh were not breached by 
the vpc would probably be precluded from transduction and may have been sheltered 
from the action of the bystander effect as well. 
TO further compound matters, the tumors grew so rapidly that it became 
necessary to euthanize many of the animals early in the follow-up perid. The delayed 
activity of IL2 (which seems to have an effect during the fourth week after 
administration) was nd seen. It is possible that the tumors grew tw quickly for an ILZ 
induced immune response fo have an impact. Ideally, all mice receiving iL2 vpc would 
have been moniwxed for an additional several weeks. By day 24, however, the tumors of 
nonrespnding and control mice were generally too large lo allow the experiment to 
continue. 
The next treatment protocol ww modified to take the aforementioned factors into 
account. Unfortunately. a change in corporate policy made it impassible to further utilize 
the IL2 vjx, which had been obtained under stipulations. Thus. it is not possible to 
estimate the potential impact these cells m y  have had under more favorable experimental 
conditions. Also, after the first treatment experiment, it was decided that three- 
dimensional measurements would be more informative. 
In the second treatment expenrnent (fig. 29). mice received an initial ~noculurn of 
5xf05 cells, which was ten times less than that used previously. Five days later, the 
tumors getierally had maximal diameters between two and three millimeters and were 
more like grapefruit seeds rather (han peanuts in size. Again, to extrapolate from in viPo 
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dm. the mmber of tumor cells present at this point may have been as many as 16 
million. An inocululn of 20 million vector producer cells (an increase 91. 33% from the 
previous experiment) was injected into the tumors. which may have represented a more 
compatible ratio of vpc b tumor cells. 
During the course of GCV wbich followed, 15 of 19 mice (78.9%) showed an 
initial response in the form of a significant reduction in tumor size. One of these animals 
(5.3%) was cured permanently, while the others eventually developed regrowth. Six 
mice were given a second injection of STK vpe. The second injection of vpc proved to 
be very traumatic for the mice. At this point in the experiment, the tumors, having gown 
for over six weeks, were typically large and highly vascular (especialiy IR thaw mice not 
showing an initial response). Mice in the BAG group were handled first. Of the five 
mice having received a primary lnoculum of BAG cells two weeks earlier, four (80%) 
died in the throes d violent seizures within seconds after the secondary BAG injection. 
The animals having larger, more vascularized tumors seemed to be the most affected. In 
several cases, it was possible to observe (through the translucent skin) ai traveling 
difference in color through superficial ascending veins. It is possible that the some of the 
cells found their way into the b i d  supply, sesulting in a fatal emhiism. 
With this in mind, three of the STK mice which had large and hghly vascular 
tumors were excluded from a second vpc injection. These mice were regrouped, and 
were eventually tabulated among the nonresponders. Six of the seven mice receiving a 
second injection of STK vpc survived the process. These mice, having already 
undergone a week long course of GCV injections, were visibly more frail, so the dose of 
GCV was reduced by 17% (from 3 mglml bid to 2.5 m@ml bid) in an effort to keep the 
mice alive. In spite of this, two of these six mice d e d  during the course of GCV 
treatment. The four remaining mice did show a significant response (p < 0.05) to both 
STK vpc injections. It is possibte that the first treatment course contributed to the 
selection of a subgroup of h4NNG ceHs wbich had developed a mechanism to enhance 
their survival; such means could include a decreased susceptibility to retraviral infection, 
interference with the retroviral integration process, altered cellular receptors, or improved 
sequestration and export of GCV or GCV-TP. 
Overall, the size differentid between the tumors in the first and second treatment 
attempts seemed to have a positive impact ~n the post-therapy prognosis. Accordingly. 
the third protocol was designed to intercept the tumors early in the growth period, when 
neoplasms were relatively small and prior to the onset uf log phase growth. For this 
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experiment, tnlenty-one mice received 2. h 1 d MNNO (NV) cells subcutaneously. Six 
days later. small tumors had begun to grow in each mouse. averaging less than two cubic 
millimeters pcr animal. These tumors were considerably smaller in this trial than they 
had been at the corresponding point in the previous experiment; where the tumors in the 
second treatment protocol were compamble in size to grapefruit seeds at day six, here the 
tumors were analogous to pinheads. At this point, STK vpc (1.5 x lo7) were intrdnced 
as a single injection; the cells flooded the tumor site and raised the neoplastic foci (wkch 
remained visibly distinct) onto a slight plateau. 
The number of tumor cells present at the time of the STK vpc injection may be 
roughly estimated at 8 million. Of course, this assumes an in vivo generation time of 24 
hours. Actually, tumor cells given at this dilution may require more time to move from 
lag phase to jog phase growth, so fewer cells may have been present. ladeed, the 
relatively small size of these tumors supports this supposilion. Thus, it is likely that the 
ratio of STK vpc to MlVNG cells was better than two to one in this case, Moreovcr, 
judging from appearance, the cells were well-delivered, as the enare tumor was in each 
case engulfed. 
As before, the responding animals generally exhibited the most pronounced 
reductive effect during the second half of GCV injection. This time interval indicate8 
either a lag between the GCV-mediated termination of DNA synthesis and the eventual 
death of the cells, a requisite threshold to GCV exposure, or the average time required fur 
the incorporation of activated GCV. Repeated injection of STK v p c  might have further 
improved the response. 
Among the three animals which were cured in the third trial. the average tumor 
volume remained relatively low throughout the experiment. In contrast, the tumor 
volumes for the six partial responders were significantly higher than the volumes for the 
nonrespoaders between days seven and 14. This suggests a relationship belween rapid 
tumor growth and the transduction efficiency of the STK vector. Tautologically, a 
mpidly growiag mass of' cells wlll be undergoing DNA replication and mitotic davision at 
a faster rate than a slower growing mass; these conditions would make more likely the 
infedion by retmviral paftides, and would also increase the incorporation frequency. A 
population of cells with a higher transductloo effic~ency (or, with a higher multiplicity of 
infection) would subsequently be expected to pfiasphorylae GCV with more zeal. As 
evidenced by X-Gal staining of tumors injected with BAG v p .  the ~ransduction 
efficiency can vary greatly among similar tumors. Moreover, as the delivery of vpc 
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seemed to be optimal in this trial, the final outcome of treatment may depend exquisitely 
on the dynarntcs of transduction. 
Overall, the response rate of 50% and the cure rate of up to 156 seen in these 
experiments are similar or better to the figures acheved by conventional strategies used 
in the treatment of ostmsarcorna. Thus, thrs work justifies furlher research in the area, 
which should eventually include clinical gene therapy trials for patients with 
osteosar coma. 
Limitations in the eff~ciency of gene transfer are most likely to be at the crux of 
the marginal success rate. Accordingly, future advances in the science of gene therapy 
must include efiorts to tmprove the gene transfer process. As has been described, the use 
of retroviruses represents an effective way to stably convey genetic material, with 
efficiencies exceeding other means by tenfold or better. Under the conchtions of these 
experiments, the transduction efficiency with the BAG gene varied from kess than one 
percent to over 14%. with an average of about six gercent (table 15). These figures give a 
basis far the transduction expectations for the STK gene. Actually, the transduction 
efficiency with the STK gene might be expected to be somewhat higher in that these vpc 
are reported to generate a higher titer than are the BAG cells. Our experiments have 
indicated that a population of as little as five percent STK-tmsduced cells is sufficient to 
mediae a significant response. Of course, in the context of the treatment experiments, 
the transduced cells were not uniformly distributed throughout the tumor 
In this series of experiments, attempts were made to improve transduction 
efficiency both through improving the vpc to tumor cell ratio and by using repeated 
injections of vpc. Each of these approaches enjoyed some success, but it is likely that 
better results would be abtained with more effiecient transduction. In the future, the 
strategy of multiple vectors (either simultaneous inlroduction of multiple genes in single 
vectors or a single wector containing an operon of several genes driven by the same 
prornoior $ might wntribute to a positive response. 
Attempts to develop a lung metstatic model 
The process of metastasis is not random, but is generally thought to represent a 
highly selective event169 which favors the survival of a subpopulation of variant cclls 
which preexist in the parental neoplasm. 170 This process consists of a requisite series of 
sequential steps that potentially metastatic cells must follow. These steps include: 
invasion by metastatic cells, embolization, persistence in the circulation, arrest in a 
distant capillary 
receptive organ. 10 
of metastasis. 
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bed. and extravasation and multiplication in the parenchyma of a 
The ~ntermption of any of these steps would preclude the dcvolopment 
Thus. sponbneous L'mtastasis lo an experimental model may be viewed as a 
highly unlikely event. The fulfillment of all the requirements for metastasis is 
compounded by factors relating to nude mice. Natural killer cells (which nude mice 
possess in high levels) are reported to be particularly adept in eradicating tumor emboli 
from the circulation. Also, young (two to six weeks old) nude mice are reported to be 
more susceptible Lo rnehshsis, while neoplasms only rarely metastasize in adult nude 
mice,172 which is likely to be related to the age-specific development of immunity. The 
mice used throughout these experiments were initially six to eight weeks old, and thus 
might be expected to have a significant level of immune responsiveness. Finally, the 
metastatic potential of human neoplasms can vary with the site of implantation to nude 
mice. f 0 
Injections into the tail-vein of nude mice were donc in an effort to develop a 
metastatic model. There is an urgent need for such models, as much of the mortality of 
patients with osteosmcoma sterns from uncontrollable spread of malignancy, most 
commonly to the luags. Here, cells introduced into venous circulation would be expected 
to enter the inferior vena cava en route to the heart. Cells reaching the right ventricle 
from the right atria would pass into the pulmonary artery and then through the branching 
network of vessels perfusing the lung. At this point, some cells might be expected to 
breech the capillary endothelium and enter the interstitiurn to colonize lung tissue. If 
conditions are right, a tumor foci might devebp and expand. Injection of vstrious 
concentrations of MNNG cells to the tail veins of over thirty mice failed to resujt in any 
tumor development beyond the caudal appendage. Ostensibly, a weak link in the chain of 
the mebsbtic process was exploited; the tumor cells may have been recognized and 
destroyed in the blood system by natural defense mechanisms, or the cells may not have 
had the capability to lave the vasculature. Alternatively, the specific population of 
MNNG cells ~nt rduced may not have contained mewzatic-eompelent variants. 
Metaxtaslis of osteosarcoma cells was eventually achieved through a different 
The fifth osteosarcoma cell line (MLM, for MNNG Lung ~efastasis) was 
derived from a lung tumor induced by metastasis of M m G  cells in one of mice 
which received an jntratibial implant. In this animal, the righl lung harbored a large 
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tumor mass, which was excised; one half was fixed for histology, and the other half was 
digested and grown in cultllre to a permanent cell line. 
Subcutaneous introduction of the MLM cells (2x106) resulted in tumor 
development in each of five mice. Unfortunately, further in vivo experimentation with 
the MLM line (including intravenous and iniraosseous injection to two groups of tea mice 
each) shows that the MLM c e l  line has no increased propensity for metastasis to the 
lung. However, this experience was ~nvtnrctive in that it offered evidence for the 
practicality of removing osteosarcoma metastases and altering the cells ex vivo with 
therapeutic intent. Efforts to develop a pulmonary metastatic model are ongoing. 
CONCLUSIONS 
These experiments have demonstrated that gene therapy has the potential for 
significant t h e r a ~ u b c  intervention in the management of osteosarcoma, Each of the five 
osteoa~Coma cell lines studied, including a novel line derived from a lung metashsis, 
were stably transduced with eacb gene of interest. Transduction with the HS-tk gene 
conferred a strong sensitivity to GCV. A potent bystander effect was demonstrated in 
vitro for eacb line. The in vivo studies support the existence of a soluble bystmder factor. 
The FIS-tk and IL2 gene products may interact to produce a heightened anti-tumor 
response. The safety and efficacy for utilizing gene therapy for the treatment of 
established tumors approached or exceeded success rates for traditional modes of 
mmi~ging osteosarcomas in patients. In ehe future, gene therapy may be used as one arm 
of a combined approach to cancer therapy. 
A fundamental refinement to this approach to geneklc therapy may be necessary to 
acheve optimal success in the realm of gene transfer. Improvement of the estimated in 
viuo transduction efficiency will like1 y result in greater overall efficacy. The 
development of vpc which generate retroviral particles at a higher titer is a logical step, 
and one which is currently being pursued. Another idea is to prime the target cells in 
such a way as to enhance the likelihood of retroviral transduction. For example. the 
polycation p romine  has been shown in vipo to improve transduction by altering the 
surface charge profile of target cells. A similar approach could be faken in vivo by co- 
injecting an  augmenting compound along with vpc. Efficacy might be further enhanced 
by the use of vpc lines containing more than one therapeutic gene in the retroviral 
comtwct. A cell-free means to deliver retroviruses is also under investigation. 
Approaches other than retroviral transduction may also prove to be important and 
feasible in the Future. The use of non-integrative viral vectors (such as &novirus and 
vaccinia vims) is currently being explored, as are various other vector-based systems. 
Improvement oE direct methds of DNA transfer (such as liposomes and electroporalion) 
may also play a role. In any event, the complete realization of .the fu'ull potential of gene 
therapy will be achieved through ingenuity and creativity as well as hard work. With 
these components in place, the future outlook for people with osteosarcoma and other 
aliments is becoming ever brighter. 
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